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1 Introduction 
Steroids can be misused in sports to enhance the athlete's performance. Usually, the 
administration aims for the anabolic effects of androgenic steroids (anabolic androgenic 
steroids, AAS). Therefore, the use of AAS, as well as the use of aromatase inhibitors 
(steroidal and non-steroidal) and other performance enhancing drugs (PEDs; for 
example, growth factors), is prohibited by the World Anti-Doping Agency (WADA) [1]. 
The present work discusses various metabolic pathways for different steroids, such as 
testosterone (T) as one of the predominant male sex hormones, androstenedione (AED) 
as an endogenous prohormone, or 17α-methyltestosterone as an exogenous steroid. The 
investigation and identification of specific metabolomes for these substances are 
essential for future antidoping analysis. The following sections will give an overview of 
the characteristics of steroids, their metabolism, and analysis.  
1.1 Steroid Hormones 
Steroid hormones have a basic structure consisting of four fused ring systems (A, B, C, 
and D ring), which give an almost planar molecule structure [2]. For a better 
understanding, the numbering system of steroids is exemplified with cholestane 
(Figure 1). The substituents can be orientated above (β-space) or under (α-space) the 
paper level [3]. 
 
Figure 1: Numbering system of steroids exemplified with cholestane (I) and its spatial arrangement of 
5α- (IIa) and 5β-configuration (IIb), adapted from [4] 
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Figure 2: Basic structures of pregnans (C21-steroids, III), androgens (C19-steroids, IV), and estranes 
(C18-steroids, V) 
Therefore, the configuration at position five has a significant influence on the spatial 
structure of the molecule. Figure 1 depicts this exemplarily for 5α-cholestane (IIa) and 
5β-cholestane (IIb). The precursor for all sex hormones is pregnenolone (PREG), 
biosynthesized from cholesterol (C27-steroid) [5]. Cholesterol is a structural element of 
cell membranes, and therefore present in all humans and animals. The side chain of 
cholesterol is cleaved by cytochrome P450 isoform 11A1 (CYP11A1) in the mitochondria 
to give PREG, which belongs to the class of pregnanes (C21-steroids) [5]. The number of 
carbons classifies basic steroid structures. Figure 2 shows the fundamental structures of 
pregnanes (III, C21-steroids), androstanes (IV, C19-steroids), and estranes (V, 
C18-steroids) [2].  
Another way of the biotransformation of cholesterol is the transformation into bile acids. 
Oxidoreductases targeting oxygens in positions 3 and 17 (HSD) and the 5α-reductase 
play an essential role in forming corticosteroids and sexual hormones [5]. Also, enzymes 
like CYP17A1 (microsomal, 17α-hydroxylase, 17,20-lyase), CYP11B1/2 (mitochondrial, 
11β-hydrolase/aldosterone synthase), CYP19A1 (microsomal, aromatase), and CYP21 
(microsomal, 21-hydroxylase) are essential in the formation of glucocorticoids, 
gestagenes, androgens, mineralocorticoids, and estrogens [5, 6]. Figure 3 shows the 
essential biosynthetic pathways for the formation of PREG, AED, cortisol, aldosterone, 
and estrone. 
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Figure 3: Essential biosynthetic pathways in the formation of pregnanes (pregnenolone), glucocorticoids 
(cortisol), gestagens (progesterone), androgens (androstenedione), mineralocorticoids (aldosterone), 
and estrogens (estrone) with involved CYP enzymes, starting from cholesterol; partially adapted from 
[4] and [6] 
1.1.1 Endogenous Steroids 
All androgens (male sex hormones) are structure-based to 5α-androstane (Figure 2, IV). 
They show effects on the strength and mass of muscles (anabolic) and the sexual 
maturation (androgenic). Male sex hormones are also present in women but show higher 
concentrations and a higher impact on humans with male sex organs. The most 
dominant androgen in men is T. It is mainly formed in the testicles (Leydig cells) via the 
intermediates PREG and AED. Enzymes involved in this formation are CYP17A1, 
3α-hydroxysteroid dehydrogenase (HSD3B2), and the aldo-keto reductase 1C3 
(AKR1C3), reducing the oxo function at C17 into the corresponding C17 hydroxy group 
(Figure 4). T is binding to the nuclear androgenic receptor (AR), mostly in the brain, 
muscles, and sex organs. Its metabolite 5α-dihydrotestosterone (5αDHT) has a higher 
affinity to the ARs. Therefore, 5αDHT is synthesized from T by the 5α-reductase 
4  Introduction 
 
(SRD5A1/2) in the effector organ (Figure 4) [7]. This pathway is described as the "front-
door-pathway". The literature also describes a second pathway for 5αDHT formation 
from allopregnanolone, called the "back-door-pathway" (not displayed in Figure 4) [8].  
The formation of weak androgens, like AED, in the adrenal cortex is controlled by the 
adrenocorticotropic hormone (ACTH) and present in males and females. 
Estrogens are formed from androgens (T, AED, and 16-hydroxyandrostendion) by 
CYP19A1 (Figure 4, aromatase) in, for example, the placenta, ovaries, fat tissue, or 
growing bones. Compared to androgens in men, estrogens in women have an impact on 
female sexual maturation. Estrogens like estradiol, estrone, or estriol also control the 
menstrual cycle regulation and pregnancy. Figure 4 shows essential biosynthetic 
pathways in the formation of important androgens and estrogens. 
 
 
Figure 4: Biosynthetic pathways including the formation of dihydrotestosterone (front-door-pathway) 
and estrogens (including involved enzymes): pregnenolone (PREG), dehydroepiandrosterone (DHEA), 
16-hydroxydehydroepiandrosterone (16OHDHEA), 16-hydroxyandrostendione (16OHAED), 
androstenedione (AED), 5α-androstanedione (5αAD), testosterone (T), 5α-dihydrotestosterone (5αDHT), 
estrone (E1), estradiol (E2), estriol (E3), hydroxysteroid dehydrogenase (HSD), aldo-keto reductase (AKR), 
SRD5A (5α-reductase); partially adapted from [8-10] 
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1.1.2 Exogenous Steroids 
T can be synthetically modified to avoid unwanted side effects or change 
pharmacokinetics. The medical use and misuse of endogenous and exogenous steroids 
can cause different side effects. Androgenic side effects caused by aromatization can be, 
for example, gynecomastia or alterations in the menstrual cycle [11]. Other unwanted 
side effects described in the literature are high blood pressure, problems in liver- and 
kidney function, and heart diseases [7, 11]. These synthetically modified substances are 
foreign to the human body; therefore, they are called exogenous steroids. Typical 
modifications are exemplified in Figure 5. As the bioavailability is too low for oral 
application, T is typically applied intramuscular or topical [12, 13]. The introduction of a 
methyl group in position 17, as seen in 17α-methyltestosterone (MT), metandienone 
(MD), dehydrochloromethyltestosterone (DHCMT), and stanozolol, increases the 
bioavailability by hindering the oxidation of the C17 hydroxy group and enables oral 
administration [14]. A double bond in position 1 (MD, DHCMT) can be introduced to 
reduce androgenic side effects by preventing the aromatization process with CYP19A1. 
Another way to prevent the aromatization process is a missing C19 methyl group 
(nandrolone) [14] (the effect of the C19 methyl group in the aromatization will be 
explained in 1.2.1). The use of aromatase inhibitors is a third option to avoid androgenic 
side effects caused by aromatization.  
 
Figure 5: Typical modifications of T resulting in methyltestosterone, metandienone, 
dehydrochlormethyltestosterone (DHCMT), nandrolone, stanozolol 
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1.2 Metabolism 
Most of the endogenous and exogenous (xenobiotics) steroids are lipophilic. They are 
predominantly converted into more hydrophilic substances to be excreted from the body. 
The conversion of the parent compound can lead to more active metabolites (for 
example, 5αDHT) or less active substances [15]. Hydroxylation, oxidation, 
hydrolyzation, and reduction are common reactions in phase-I-metabolism [7]. These 
reactions lead to more hydrophilic metabolites, which are excreted faster. The oxidation 
reactions in metabolism are often correlated to cytochrome P450 enzymes (CYPs) or 
occur due to the autoxidation of the parent compound. CYP3A4 is one of the most 
dominant enzymes involved in human metabolism. Especially in steroid metabolism, the 
5α-reductase and HSD3 play an essential role in forming reduced metabolites [15, 16].  
Typically, the parent compound or the phase-I-metabolites will be conjugated to sulfate 
or glucuronic acid in phase-II-metabolism [7]. Phase-II-metabolites are even more 
hydrophilic than the corresponding aglycons (phase-I-metabolites) or the parent 
compounds. UDP-Glucuronosyltransferase (UGT) enzymatically binds glucuronic acid 
to functional groups in the molecule. The reaction to glucuronidated metabolites shows 
the predominant way of phase-II-metabolization in the human body [17]. 
Sulfotransferase (SULT) and the co-factor 3’-phosphoadenosin-5’-phosphosulfate 
(PAPS) catalyze sulfonation of phase-I-metabolites and parent compounds [7]. Other 
phase-II-reactions such as methylation or acetylation [17] are not much described for 
steroid metabolism. 
1.2.1 Hydroxylation 
The hydroxylation of steroids is one of the pathways in the metabolization process. 
Various CYP enzymes are involved in steroid hydroxylation [16]. The oxygen transfer to 
the molecule, catalyzed by CYP enzymes, is a mono-oxygenation. Hence, cytochrome 
P450 enzymes are assigned to the class of monooxygenases. The CYP structure consists 
of a minimum of two protein substructures. First, the heme protein, containing iron as 
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the central atom, and second the NADPH-CYP oxidoreductase, which transfers electrons 
to the heme system [18]. 
Hydroxylation reactions for T are described in positions 1β, 2, 6, 11, 15 (all α and β) and 
16β [19-25]. Yamazaki et al. described five different hydroxy metabolites of progesterone 
after CYP2C19 incubation (2β, 6β, 16α, 17α, and 21) [19]. The predicted mechanism for 
the hydroxylation is exemplified for T in the 6β position in Figure 6. Renidc et al. 
predicted that the iron(IV)-oxo porphyrin radical is the active species in this reaction 
(compound I) [26]. This substructure can activate the C-H bond in the steroid molecule. 
The abstraction of one hydrogen atom yields an alkyl radical [27]. After that, the formed 
hydroxy group reorientates, and a C-O bond is formed. This reaction ends in the 
hydroxylated metabolite and an oxygen-free heme system. Binding oxygen, two electron 
transfers, and water loss after protonation, the so-called "oxygen rebound", reactivate 
the monooxygenase [28, 29]. 
CYP3A4 is one of the dominant enzymes expressed in the liver and other tissues involved 
in the metabolization of xenobiotics. Due to its variable binding site, CYP3A4 is a 
relatively unspecific enzyme and hence plays a role in the formation route of many 
metabolites.  
CYP1A2 and CYP1B1 were shown to be involved in forming A-ring hydroxylation in 
estrogens [30]. Hydroxylated intermediates in the aromatization process are also 
described in the literature [4, 31].  
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Figure 6: Proposed mechanism of the hydroxylation of 3-oxo-4-ene-steroids with CYP, exemplified on the 
formation of 6β-hydroxymethyltestosterone; adapted from [26] 
1.2.2 Aromatization of Androgens 
Aromatase is a specific enzyme because of its tight binding site. Only planar substrates 
can be metabolized [32]. Sugimoto et al. showed that the C19 methyl group of AED is 
orientated directly to the enzyme's heme group [33].  
CYP19A1 catalyzes the formation of estrogens from androgens. Three hydroxylation 
processes are involved in the aromatization process [34]. The estradiol formation from 
T, depicted in Figure 7, exemplifies this reaction. In the first step, C19 is hydroxylated to 
result in the primary alcohol. After a second hydroxylation at C19 and the loss of water, 
the intermediate aldehyde is formed. These two monooxygenations follow the hydrogen 
abstraction/oxygen rebound mechanism described in 1.2.1 (Figure 6) [29]. The first step 
is considered as the rate-limiting factor [35]. The third step of aromatization is the 
elimination of C19. The mechanism which ends in the loss of formic acid and 
aromatization of the A-ring is discussed controversially in the literature. The three 
proposed mechanisms are shown in Figure 8. Yoshimoto and Guengerich proposed two 
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different pathways that are shown in Figure 8 [34]. Pathway I describes ferric peroxide 
as the mechanism's active iron species. The second hypothesis (pathway II) shows 
compound I as active iron species, as in the first two aromatization steps. In both 
pathways, the 1β-proton and the 19 methyl group (as formic acid) are cleaved from the 
molecule. Those two positions seem essential for the aromatization process [34, 36].  
Hosoda et al. described the last step to be not enzymatically catalyzed. In their hypothesis 
(Figure 8, III), the existence of 2β-hydroxylated compounds in the aromatization builds 
the third proposed pathway [31, 37]. The hydroxylation in position 2β results in the 2β-
hydroxy-19-aldehyde intermediate. This structure undergoes a complete conversion to 
estrogen after a basic attack at C19 (loss of water [C2] and formic acid [C19]) [31].  
 
 
Figure 7: Aromatization process of testosterone; every hydroxylation consumes one oxygen and NADPH 
molecule; C19 methyl group is finally cleaved off as formic acid 
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Figure 8: The three discussed pathways for the third step in the aromatization process, described by 
Yoshimoto et al. (I + II) and Hosoda et al. (III) [31, 34] 
1.2.3 Metabolism of 17α-Methyltestosterone 
The model substance of this project is MT. As described in 1.1.2, MT is an exogenous 
steroid. The methylation in position 17 allows the oral administration. MT intake, as a 
performance enhancing drug (PED) in sport, is prohibited by the WADA in and out of 
competition (prohibited at all times) [1]. Therefore, the metabolism plays an important 
role in the detection of MT abuse. Several metabolites are already described, albeit 
mainly in animals (horse, greyhound, heifer) [38-44]. Besides some small amounts of 
hydroxylated compound (in position C6, C16, C17), the reduction to dihydrogenated 
(dihydromethyltestosterone, DHMT) and fully reduced (tetrahydromethyltestosterone, 
THMT) metabolites showed to be the main metabolization pathway. Furthermore, the 
combination as a reduced and hydroxylated compound and epimerization in position 17 
are also described [42]. 
The metabolome of MT in human, however, is not thoroughly investigated. Pozo et al. 
described the two fully reduced metabolites 17α-methyl-5β-androstane-3α,17β-diol 
(5βTHMT) and 17α-methyl-5α-androstane-3α,17β-diol (5αTHMT) as main metabolites 
in the human metabolism [45]. This was done by investigations on mice with humanized 
liver and confirmed in humans. Typically, MT administration in antidoping analysis is 
traced by these two reduced metabolites using GC-MS analysis after cleavage of the 
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phase-II-glucuronides [46]. Earlier this year, Martinez-Brito et al. reported the excretion 
of 2ξ-hydroxy-17α-methyltestosterone (2ξOHMT), 4-hydroxy-17α-methyltestosterone 
(4OHMT), and 6β-hydroxy-17α-methyltestosterone (6βOHMT) in small amounts beside 
the main metabolites 5αTHMT and 5βTHMT in man, after the administration of 10 mg 
MT [47]. 
1.3 Steroid Analysis 
To detect the use of performance enhancing drugs (PED) [48], typically gas 
chromatographic (GC) or liquid chromatographic (LC) systems coupled to a mass-
spectrometric detector are used (GC-MS[/MS], LC-MS[/MS]) [49, 50]. Both systems 
have their advantages and disadvantages. Today, GC-MS methods show high selectivity 
and resolution for complex matrices. Therefore, mostly GC-MS(/MS) methods are used 
in routine antidoping analysis for steroids. The major disadvantage of these methods is 
laborious sample preparation. As phase-II-metabolites are poorly or not detectable in 
GC-MS analysis, the sample preparation generally includes the cleavage of glucuronides. 
After extraction of free and liberated compounds, the samples are derivatized to TMS 
derivatives, as shown in 3.2.3.1, partially leading to derivatization artifacts (for example, 
hydroxylation in C6 at MT; MT reference compound showed minor amounts of 
6-hydroxy-17α-methyltestosterone after TMIS derivatization, results have been omitted 
for the sake of brevity). However, the derivatization also shows the advantage of a better 
separation and hence reliable identification of possible PED. After electron ionization 
(EI), trimethylsilylated compounds show a specific fragmentation pattern suitable for 
structure elucidation/identification [51]. The observation of specific fragmentation 
patterns of the compounds (MS/MS experiments) lowers the background noise. 
Therefore, tandem mass spectrometry is typically used to lower the limit of detection 
(triple-quadrupole-MS [QQQ-MS]).  
LC-MS(/MS) methods are often used in endocrinological investigations [52-54]. 
Compared to the standard GC-MS(/MS) methods, the detection of thermolabile 
substances and intact phase-II-metabolites is possible in LC-MS analysis [55, 56]. 
12  Introduction 
 
Usually, the run time is shorter than in GC-MS analysis, and the derivatization step is 
often not necessary [56]. Nevertheless, the easier sample preparation and improvement 
in run time typically go along with a lower separation efficiency than GC-MS methods. 
Compared to EI, the electrospray ionization (ESI) often used in LC-MS analysis [besides 
atmospheric pressure chemical ionization (APCI) and atmospheric pressure photo 
ionization (APPI)] may result in decreased sensitivity for some compounds and 
metabolites. For example, fully reduced metabolites as 5α/βTHMT are poorly ionized 
with ESI [56].  
For the untargeted approach, high-resolution MS (HRMS, GC-EI-(Q)TOF, LC-ESI-
(Q)TOF) is the method of choice [57]. Accurate mass together with tandem mass 
spectrometry is a useful tool in the structure elucidation of unknown compounds. 
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2 Aim of this Work 
MT belongs to the class of exogenous steroids and is prohibited by the WADA at all times 
[1], as described in 1.2.3. MT administration was detected in about 1% of all adverse 
analytical findings (AAF) for AAS in the past years. Figure 9 depicts the number of AAF 
for MT from 2014 to 2019.  
Mainly, MT is metabolized similarly to its endogenous analogon T, resulting in  5αTHMT 
and 5βTHMT. To detect its misuse, MT is mainly identified by detection of these reduced 
metabolites. GC-MS analysis is the method of choice because of the low ionization of 
these substances with ESI. Only recently, the U.S. cycling athlete Barbara Gicquel 
(80 years) was tested positive for 5αTHMT and 5βTHMT [46].  
Hydroxylated metabolites of MT with intact 3-oxo-4-ene substructure might be a 
possible way to identify MT abuse with an ESI-MS/(MS) coupled method. The advantage 
of such a method would be faster analysis times, much faster sample preparation, and 
complementary data to GC-MS of THMT as long term marker. Several hydroxylation 
reactions for different AAS are discussed in literature (see 1.2.1). For example, Joseph 
found 2β-hydroxyandrost-4-ene-3,17-dione to be the major hydroxylated metabolite 
after AED administration to one healthy male volunteer [4]. In this project, a method 
able to separate and identify different hydroxy metabolites of MT shall be developed.  
 
Figure 9: Number of adverse analytical findings of MT from 2014 to 2019 reported by the WADA 






2014 2015 2016 2017 2018 2019
14  Aim of this Work 
 
Based on literature results for other AAS, 2β-hydroxy-17α-methyltestosterone 
(2βOHMT), 2α-hydroxy-17α-methyltestosterone (2αOHMT), 4-hydroxy-17α-
methyltestosterone (4OHMT, oxymesterone), and 6β-hydroxy-17α-methyltestosterone 
(6βOHMT) were selected as target analytes after enzymatic hydroxylation. As 2βOHMT 
and 2αOHMT are not commercially available, they had to be synthesized and 
characterized (chapter 4.1) before further in vitro and in vivo studies. 4OHMT is 
commercially available, but as it is a byproduct of the 2α/βOHMT synthesis, it was also 
synthesized in house.  
Orthogonal analytical approaches were tested to achieve the best selectivity for the 
separation of hydroxylated metabolites of MT. For this purpose, the common systems for 
steroid analysis, GC-MS/(MS) after derivatization and LC-MS(/MS), together with 
supercritical fluid chromatography (SFC) as orthogonal techniques, were investigated to 
be used as the chromatographic separation system (chapter 4.4). 
In vitro studies with CYP3A4, CYP2c19, CYP1A2, and CYP1B1 shall investigate the 
formation of four different hydroxy metabolites, focusing on the formation of 2βOHMT 
as a possible long-term marker for MT abuse (chapter 4.5.1-4.5.3). In addition to these 
in vitro studies, an in vivo study was implemented to show the impact of hydroxylated 
metabolites in human metabolism of MT (chapter 4.6). 
The second project investigated the influence of 2βOHMT in the third step of the 
aromatization of MT (1.2.2). 19-hydroxy-17α-methyltestosterone (19OHMT) was 
synthesized and characterized for this project. This study focused on the formation of 
2βOHMT and 19OHMT after MT incubation with CYP19A1 (chapter 4.5.4). 
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3 Material and Methods 
3.1 Material 
Table 1: Steroids and reference material 
17α-Methyltestosterone Sigma Aldrich (Taufkirchen, Germany) 
19-Hydroxyandrost-4-ene-3,17-dione Carbosynth Ltd. (Compton, United 
Kingdom) 
2α-Hydroxyandrost-4-ene-3,17-dione in house synthesized 
2β-Hydroxyandrost-4-ene-3,17-dione in house synthesized 
4-Hydroxy-17α-methyltestosterone TRC (North York, USA) 
6β-Hydroxy-17α-methyltestosterone Steraloids (Newport, USA) 
Androst-4-ene-3,17-dione VWR (Dresden, Germany) 
Mefruside BOC Science (New York, USA) 
Metandienone Sigma Aldrich (Taufkirchen, Germany) 
Testosterone-d3 Sigma Aldrich (Taufkirchen, Germany) 
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Table 2: Solvents, reagents, and materials 
Acetone VWR (Dresden, Germany) 
Acetonitrile LC-MS grade Fisher (Schwerte, Germany) 
Acetonitrile p.a. VWR (Dresden, Germany) 
Acetyl chloride Sigma Aldrich (Taufkirchen, Germany) 
Ammonium fluoride  Sigma Aldrich (Taufkirchen, Germany) 
Ammonium iodide  Sigma Aldrich (Taufkirchen, Germany) 
Argon Air liquide (Düsseldorf, Germany) 
Cyclohexene Sigma Aldrich (Taufkirchen, Germany) 
CYP19A1 + oxidoreductase Corning Supersomes (New York, USA) 
CYP1A2 Corning Supersomes (New York, USA) 
CYP1B1 Corning Supersomes (New York, USA) 
CYP2C19 Corning Supersomes (New York, USA) 
Dichloromethane VWR (Dresden, Germany) 
DMSO Merck (Darmstadt, Germany) 
Ethanethiole Sigma Aldrich (Taufkirchen, Germany) 
Ethanol VWR (Dresden, Germany) 
Ethyl acetate VWR (Dresden, Germany) 
Formic acid, LC-MS grade Sigma Aldrich (Taufkirchen, Germany) 
Glacial acetic acid Merck (Darmstadt, Germany) 
Helium Air liquide (Düsseldorf, Germany) 
HLM pooled from 50 donors BD Bioscience (Milan, Italy) 
Hydrochloric acid  Fisher (Schwerte, Germany) 
Hydrogen peroxide 30 % Sigma Aldrich (Taufkirchen, Germany) 
Methanol MS quality Fisher (Schwerte, Germany) 
Methanol p.a. VWR (Dresden, Germany) 
Methylmagensium bromide solution 
(3N) 
Sigma Aldrich (Taufkirchen, Germany) 
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MSTFA Chemische Fabrik Karl Bucher 
(Waldstetten, Germany) 
NADPH regenerating system solution A Corning Gentest (New York, USA) 
NADPH regenerating system solution b Corning Gentest (New York, USA) 
Nitrogen Air liquide (Düsseldorf, Germany) 
Phosphate-buffer-system 0.5 M BD Bioscience (Milan, Italy) 
Potassium carbonate Sigma Aldrich (Taufkirchen, Germany) 
Potassium hydrogencarbonate Sigma Aldrich (Taufkirchen, Germany) 
Potassium iodide Sigma Aldrich (Taufkirchen, Germany) 
Pyridine VWR (Dresden, Germany) 
Sodium hydroxide Sigma Aldrich (Taufkirchen, Germany) 
Sulfuric acid 96 % Merck (Darmstadt, Germany) 
TBME AppliChem (Darmstadt, Germany) 
Tetrahydrofuran Sigma Aldrich (Taufkirchen, Germany) 
Water LC-MS grade LaboStar 2-DI/-UV ultrapure water 
system; SG Wasseraufbereitung und 
Regenerierstation GmbH (Barsbüttel, 
Germany) 
β-Glucuronidase from Escherichia coli 
(>140 U/mL) 
Roche Diagnostics (Mannheim, Germany) 
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3.2 Methods 
Table 3 depicts a short overview of the methods used in this thesis. The methods details 
will be introduced in subsections 3.2.1-3.2.3. 
Table 3: Overview of the used methods, showing the used instruments, their field of application in this 
thesis, and the method shortcut 
Instrument Field of Application Method 
LC-UV Purification a) 
HPLC-ESI-MS Synthesis monitoring b) 
HPLC-ESI-QTOF-MS Structure elucidation c) 
SFC-ESI-QQQ-MS In vitro/in vivo studies (MT) d) 
SFC-ESI-QQQ-MS In vitro studies (AED) e) 
GC-EI-MS Synthesis monitoring f) 
GC-EI-MS Synthesis monitoring g) 
GC-EI-QTOF-MS Structure elucidation h) 
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3.2.1 Liquid Chromatography  
3.2.1.1 LC-UV 
The LC-UV system was used for the semipreparative separation of 2α/β- and 4-hydroxy-
17α-methyltestosterone. Therefore, a fraction collector was used to collect the fractions 
of interest. The sample was loaded on silica and placed on top of the column. Separation 
was achieved using the following method. 
Table 4: Parameters for LC purification method a) 
Device Biotage Isolera One (Uppsala, Sweden) 
Column Biotage SNAP Ultra 10 g (Uppsala, Sweden) 
Solvent A Hexane 
Solvent B Ethyl acetate  
Gradient 40% B for 2 column volumes (CV) 
to 60% B at 15 CV 
60% B for 2 CV 
Flow rate 12 mL/min 
UV parameters 254 nm 
Threshold 15 mAU 
Fraction collector Peak based; automatically   
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3.2.1.2 HPLC-ESI-MS 
HPLC-ESI-MS was used to monitor the synthesis progress. Therefore 10 µL aliquots of 
the reaction mixture were diluted with methanol to a resulting 10 ppm solution. Test 
samples from synthesis raw product were prepared by diluting a ~1000 ppm stock 
solution (in methanol). 
Table 5: HPLC-ESI-MS parameters for method b) 
Device Agilent 1260 Infinity System (Santa 
Clara, USA) 
Agilent 6130B Single Quadrupole MS 
System (Santa Clara, USA) 
Column Agilent ZORBAX Eclipse Plus RP C18  
(1.8 µm, 2.1 x 100 mm) 
Temperature 25 °C ± 0.8 °C 
Injection volume 1 µL  
Solvent A H2O/FoOH (99.9:0.1; v:v) 
Solvent B ACN/FoOH (99.9:0.1; v:v) 
Gradient 5% B at 0 min 
95% B at 10 min 
95% B at 11 min 
5% B at 11.5 min 
5% B at 12 min 
Flow rate 0.250 mL/min 
MS parameters Full scan mode 70-1000 (m/z) 
Gas temperature 350°C 
Gas flow 12 L min 
Nebulizer pressure 35 psi 
Capillary voltage 3000 V 
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3.2.1.3 HPLC-ESI-QTOF-MS 
HPLC system equipped with a high-resolution quadrupole time-of-flight mass 
spectrometer (QTOF) with ESI was used to obtain the accurate masses of underivatized 
substance. Therefore methanolic solutions (1 ng/mL) of the compounds were prepared. 
Table 6: HPLC-ESI-QTOF-MS parameters for method c) 
Device Agilent 1290 Infinity II (Santa Clara, USA) 
Agilent 6550 iFunnel QTOF-MS (Santa Clara, 
USA) 
Column Agilent Poroshell 120 Chrial-V  
(2.7 µm, 2.1 x 100 mm) 
Temperature 30 °C ± 0.8 °C 
Injection volume 10µL 
Solvent A H2o/FoOH (99.9:0.1; v:v) + 1mM NH4F   
Solvent B ACN/H2O/FoOH (97.4:2.5:0.1; v:v:v)  
+ 1 mM NH4F 
Gradient 10% B at 0 min 
40% B at 8 min 
95% B at 10 min 
95% B at 12 min 
10% B at 13 min 
Flow rate 0.800 mL/min 
MS parameters Gas temperature 200°C 
Gas flow 13 L/min 
Nebulizer pressure 35 psi 
Sheath gas temperature 375 °C 
Sheath gas flow 11 L/min 
Capillary voltage 3500 V 
Nozzle voltage 500 V 
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3.2.2 Supercritical Fluid Chromatography 
3.2.2.1 SFC-ESI-QQQ-MS 
SFC-ESI-QQQ-MS was used for in vivo and in vitro study investigation. Method d) (MT) 
and method e) (AED) only differ in the target analytes and their ion transitions 
monitored (Table 8 and Table 9). 
Table 7: SFC-ESI-QQQ-MS parameters, method d) + e) 
Device Agilent 1260 Infinity II SFC System 
Agilent 6495B Triple Quadrupole  
Column Agilent Poroshell 120 Chrial-V  
(2.7 µm, 2.1 x 100 mm) 
Temperature 23 °C ± 0.8 °C 
Injection volume 10 µL (double loop overfill) 
Solvent A CO2 (precompressed) 
Modifier Methanol 
Gradient 10% Modifier at 0 min 
20% Modifier at 6 min 
30% Modifier at 8 min 
10% Modifier at 10 min 
Flow rate 1.200 mL/min 
Makeup solvent MeOH/H2O/FoOH (97.4:2.5:0.1; v:v:v)  
+ 1mM NH4F 
Makeup flow rate 0.150 mL / min 
MS parameters Gas temperature 210°C 
Gas flow 17 L/min 
Nebulizer pressure 40 psi 
Sheath gas temperature 350 °C 
Sheath gas flow 11 L/min 
Capillary voltage 4000 V 
Nozzle voltage 500 V 
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Table 8: Precursor and product ions of 17α-methyltestosterone, its hydroxy metabolites and internal 
standards for MRM experiments, method d) 
Compound Precursor (m/z) Product ion 
(m/z)  
17α-Methyltestosterone 303.2  109.1  
 97  
2α-Hydroxy-17α-methyltestosterone 319.2  283.1 
 121  
 107.1  
2β-Hydroxy-17α-methyltestosterone 319.2  283.1 
 121 
 107.1  
4-Hydroxy-17α-methyltestosterone 319.2  189 
 125 
 113 
6β-Hydroxy-17α-methyltestosterone 319.2  283.2 
 225.1 
 173.1 
19-Hydroxy-17α-methyltestosterone 319.2  283.1 
 157 
Testosterone-d3  292.2  109 
 97 
Gluc-testosterone-d3  468.3  109 
 97 
 84.9 
Mefruside  383  284.9 
 81 
Metandienone 301.2  149 
 121 
 
Testosterone-d3, gluc-testosterone-d3, and mefruside were used as internal standards in 
the urine samples. MD was used as an internal standard in the incubation studies. 
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Table 9: Precursor and product ions of androst-4-ene-3,17-dione, its hydroxy metabolites, and the 
internal standard MD for MRM experiments; method e) 
Compound Precursor (m/z) Product ion 
(m/z)  
Androst-4-ene-3,17-dione 287.2  109.1  
 97  
2α-Hydroxy-androst-4-ene-3,17-dione 303.2  267.1  
 158.9  
 93  
2β-Hydroxyandrost-4-ene-3,17-dione 303.2  267.1 
 171  
 95 
6β-Hydroxyandrost-4-ene-3,17-dione 303.2  226.9 
 209.1 
 97  
19-Hydroxyandrost-4-ene-3,17-dione 303.2  255.2 
 156.9 
 97 
Metandienone 301.2  149 
 121 
 
MD was used as an internal standard in the incubation studies. 
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3.2.3 Gas Chromatography 
Gas chromatography, coupled with mass spectrometric detection, was used for product 
identification and characterization. The samples were measured underivatized, as 
mono-TMS or per-TMS derivative. 
3.2.3.1 Derivatization 
For GC analysis of steroids, two different derivatization-methods were used to yield the 
per-TMS (derivatization with catalyst) or mono/bis-TMS (derivatization without 
catalyst) derivatives. A mixture of N-methyl-N-(trimethylsilyl)trifluoracetamide 
(MSTFA), ammonium iodide (NH4I) and ethanethiol (1000:2:3, v/w/v) was used to 
generate trimethyliodosilane (TMIS) in situ and form the per-TMS derivatives. Figure 10 
shows the reaction mechanism. Donike et al. and Geyer et al. introduced this well-
described method used in antidoping laboratories worldwide [58, 59]. The trimethylsilyl 
ethers were formed directly from the corresponding hydroxy group, the trimethylsilyl 
enol ethers after enolization of the oxo function. Ethanethiol reacts with iodine to form 
hydrogen iodide (antioxidant).  
Derivatization with MSTFA without any catalyst yielded the derivatization of sterically 
unhindered hydroxy groups. Position 17 of MT was not derivatized because the hydroxy 
group is sterically hindered. Generally, only hydroxy and not oxo groups form the 
corresponding trimethylsilyl ethers.  
 
Figure 10: In situ formation of TMIS from MSTFA/NH4I/ethanethiol (1000:2:3, v/w/v) 
 






















Figure 11: Reaction scheme of derivatization of 2βOHMT with TMIS; the resulting per-TMS derivatives 
3,5-diene-2,3,17-triol tris-TMS (A) and 2,4-diene-2,3,17-triol tris-TMS (B) from the reaction of 
2β-hydroxy-17α-methyltestosterone 
 
Figure 12: Reaction scheme of derivatization of 2βOHMT with MSTFA; the resulting mono-TMS 
derivative 4-ene-2,17-diol-2-TMS (C) from the reaction of 2β-hydroxy-17α-methyltestosterone 
The resulting mono- (C) and per-TMS derivatives (A and B) are exemplified with 
2β-hydroxy-17α-methyltestosterone and shown in Figure 11 and Figure 12. 
For TMIS derivatization, 10 µL (1000 µg/mL) of the steroid solution was transferred into 
a test tube and dried. An amount of 90 µL MSTFA and 10 µL of derivatization solution 
(MSTFA/NH4I/ethanethiol; 100:2:3, v/w/v) were added, and the solution was heated to 
75 °C for 30 minutes. 
For MSTFA derivatization, 10 µL of the steroid solution (1000 µg/mL) was transferred 
into a test tube and dried. An amount of 100 µL MSTFA was added, and the solution was 
heated to 75 °C for 20 minutes. The sample was dried under nitrogen at 75 °C, and the 
residue was dissolved in 100 µL ethyl acetate. 
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3.2.3.2 GC-EI-MS/QTOF-MS 
For the characterization of synthesis products, a gas chromatograph coupled to a single 
quadrupole mass selective detector was used [Agilent 5975C MSD, method f) & g)]. High-
resolution mass spectrometry [Agilent 7200 accurate mass QTOF, method h)] was used 
to identify the products. Both systems were equipped with an EI source. Method g) uses 
a different oven temperature program to separate per-TMS derivatives; all other 
parameters are like method f). 
Table 10: GC-EI-MS parameters applied in method f) 
Device Agilent 7890A gas chromatograph  
(Santa Clara, USA)  
Agilent 5975C mass selective detector (MSD)  
(Santa Clara, USA) 
Column Agilent HP1-Ultra (17 m, 200 µm, 0.11 µm) 
(Santa Clara, USA) 
Injection volume 2 µL 
Carrier gas Helium at 1 mL/min, constant flow 
Inlet parameters Split injection 1:10, temperature 300 °C 
Oven temperature program 183 °C, 3 °/min to 232 °C, 40 °C/min to 310 °C,  
2 min hold 
MS parameters Electron ionization with 70 eV at 230 °C 
Full scan mode 40-750 m/z 
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Table 11: GC-EI-MS parameters applied in method g) 
Device Agilent 7890A gas chromatograph  
(Santa Clara, USA) 
Agilent 5975C mass selective detector (MSD)  
(Santa Clara, USA) 
Column Agilent HP1-Ultra (17 m, 200 µm, 0.11 µm)  
(Santa Clara, USA) 
Injection volume 2 µL 
Carrier gas Helium at 1 mL/min, constant flow 
Inlet parameters Split injection 1:10, temperature 300 °C 
Oven temperature program 150 °C, 50 °/min to 240 °C, 3 °C/min to 266 °C, 
50 °C to 310 °C,  
3 min hold 
MS parameters Electron ionization with 70 eV at 230 °C 
Full scan mode 40-750 m/z 
 
Table 12: GC-EI-QTOF-MS parameters applied in method h) 
Device Agilent 7890B gas chromatograph 
(Santa Clara, USA)  
Agilent 7200 accurate mass selective QTOF  
(Santa Clara, USA) 
Column Agilent HP1-Ultra (17 m, 200 µm, 0.11 µm)  
(Santa Clara, USA) 
Injection volume 0.2 µL 
Carrier gas Helium at 1 mL/min, constant flow 
Inlet parameters Split injection 1:10, temperature 280 °C 
Oven temperature program 200 °C, 1 °/min to 245 °C, 40 °C/min to 310 °C  
2 min hold 
MS parameters Electron ionization with 70 eV at 230 °C 
Full scan mode 40-750 m/z 
Scan speed 50 Hz (200 ms/spectrum) 
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3.2.4 Synthesis of Reference Material 
3.2.4.1 2α/β- and 4-Hydroxy-17α-methyltestosterone 
 
Figure 13: Chemical structures of the educt 17α-methyltestosterone (1) and the three desired products 2β-
hydroxy-17α-methyltestosterone (4), 2α-hydroxy-17α-methyltestosterone (5) and 4-hydroxy-17α-
methyltestosterone [oxymesterone] (6) 
The synthesis of 2α-, 2β-, and 4-hydroxy-17α-methyltestosterone started from the 
commercially available MT [60]. An amount of 1.66 g MT (0.005 mol) was dissolved in 
110 mL methanol and cooled to 0 °C. A solution of 2.3 mL sodium hydroxide (6 N) and 
1.8 mL hydrogen peroxide 30% was added dropwise. The temperature was controlled to 
be in-between 0 and 5 °C. After stirring the solution for 24 hours at 0 °C, the reaction 
was stopped by adding 25 mL of water. The reaction mixture volume was decreased to 
about 50 mL by evaporation of the solvent under reduced pressure and extracted three 
times, with 50 mL of dichloromethane (DCM). The combined organic phases were 
washed two times with 50 mL of water and dried with sodium sulfate. After evaporation 
under reduced pressure, 1.3431 g (77%) of white powder were yielded.  
An aliquot of 0.392 mg residue was dissolved in 16 mL acetone, and 0.8 mL sulfuric acid 
25% was added slowly. The reaction mixture was stirred at room temperature for 
72 hours. After addition of 100 mL water, the resulting solution was extracted three 
times with 50 mL DCM. The organic phases were combined, washed with 100 mL water, 
dried with sodium sulfate, and evaporated under reduced pressure. LC purification 
[method a), 3.2.1.1] of the resulting oily residue yielded 18 mg 4-hydroxy-17α-
methyltestosterone (0.06 mmol) and 56 mg of the 2α/β-hydroxy-17α-
methyltestosterone mixture (0.17 mmol). 




Figure 14:Chemical structures of 19-hydroxyandrost-4-ene-3,17-dione (left) and the expected product 19-
hydroxy-17α-methyltestosterone (right) 
19-Hydroxy-17α-methyltestosterone (19OHMT) was synthesized from 
19-hydroxyandrost-4-ene-3,17-dione (19OHAED). The synthesis steps were adapted 
from Liao et al. [61] and are shown in Figure 14. Methanol (10 mL) was cooled to 0 °C 
and 1 g of acetyl chloride was slowly added dropwise. The solution was stirred for 
15 minutes at 0 to 5 °C. An amount of 1.00 g 19OHAED (0.003 mol) was added to this 
solution, and the reaction was carried out for five hours at 0 °C. After this, the reaction 
mixture was poured into 75 mL water containing 2.5 g potassium carbonate, which was 
previously cooled to 0 °C. After one hour of stirring, the obtained residue was separated 
by suction filtration and washed with water. 
The residue was dissolved in 10 mL toluene containing 38 µL of pyridine and heated 
under reflux for one hour. After cooling the solution to room temperature, the water 
phase was separated from the organic reaction mixture. The reaction temperature was 
held between 10 and 15 °C when a solution of 6.6 mL CH3MgBr (0.05 mol/L in diethyl 
ether) and 3.4 mL of dry tetrahydrofuran was added dropwise. After 24 hours of stirring 
at 40 to 45 °C, the reaction was stopped by cooling the solution to 15 °C, adding 1 mL of 
water, and 10 mL methanol dropwise. After that, a solution of 1.5 mL concentrated 
hydrochloric acid (36%) and 10 mL water was slowly added to the reaction mixture and 
adjusted to pH=2. The temperature of the solution was held at 50 to 55 C for two hours 
and cooled down to 30 °C after this. The solution was concentrated under reduced 
pressure, then added to previously cooled water (0 °C) and this reaction mixture was 
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stirred for one hour. The residue was separated by suction filtration, washed until the 
residue had a neutral pH, and dried over potassium hydroxide. This reaction yielded 
487 mg of yellow-brown crude product. The residue was purified by washing it with ethyl 
acetate to give ~3 mg of yellowish crystals (0,01 mmol, most of the residue seemed to be 
unconsumed educt). 
3.2.5 Structure Confirmation of Synthesized Products 
Nuclear magnetic resonance spectroscopy (NMR) was used to confirm the structure of 
the synthesized references 2αOHMT, 2βOHMT, and 4OHMT. 
High-resolution mass spectrometry (HRMS) was used to identify the elementary 
composition of the synthesized reference compounds. 
3.2.5.1 NMR 
NMR spectra (500 Hz [1H] and 125 Hz [13C]) were measured at 298 K on a Bruker Avance 
III 499 instrument. The 5 mm inverse probe head was actively shielded with a z-gradient 
coil. Deuterated chloroform or DMSO was used as solvent. 
The following experiments were measured for the structure confirmation: 
1H, 13C, DEPT (Distortionless Enhancement by Polarization Transfer), 1H,1H-COSY 
(Heteronuclear Correlation Spectroscopy), HMQC (Heteronuclear Multiple Quantum 
Coherence), and HMBC (Hetero Multiple Bond Correlation). 
3.2.5.2 HRMS 
LC-HRMS data was obtained using an Agilent 6550 iFunnel QTOF-MS. Permanently 
performed mass axis calibration and a high resolution (> 10,000) achieved high mass 
accuracy.  
GC-HRMS was carried out on an Agilent 7200 accurate mass QTOF-MS. The calibration 
of the mass axis was performed prior to each run. 
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3.2.6 Incubation Experiments 
 
Figure 15: Incubation protocol for the in vivo studies adapted from [62] 
Incubation studies were performed with MT. AED served as positive control. A control 
sample (negative) without any enzyme was prepared for every compound.  
  
226 µL 0.1 M phosphate buffer (pH 7.4) 
+ 12.5 µL solution A (NADP+ + glucose-6-phosphat) + 2.5 µL solution B (glucose-6-
phosphate dehydrogenase)
+ 2.5 µL substrate solution (100 µg/mL in methanol) 
 incubation for 5 minutes at 37 °C
+ 6.5 µL enzyme solution (CYP1A2, CYP1B1, CYP2C19 or CYP19A1) or HLM
incubation for 24 hours at 37 °C
+ 225 µL acetonitrile + 25 µL internal standard metandienone (10 µg/mL in 
acetonitrile)
+ 1.0 mL 0.1M phosphate buffer (pH7.4) and carbonate/bicarbonate solid buffer 
(8.4 g  NaHCO3/13.8 g K2CO3)  pH 9-10
centrifugation at 4500 g for 5 minutes
supernatant extracted two times with 2 mL TBME
evaporation of organic phase under nitrogen at 40 °C
+ 250 µL methanol  SFC-ESI-QQQ-MS analysis
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3.2.7 Human Urine Samples 
 
Figure 16: Protocol for the sample preparation of urine analysis 
The protocol for steroid extraction from urine samples was adapted from Mareck et al. 
[63].  
 
4 mL urine + 750 µL 0.8 M phosphate buffer (pH 7) 
+ 100 µL internal standard (2 µg/mL testosterone-d3 + gluc-testosterone-d3 + 
mefruside)
+ 50µL glucuronidase
1 hour incubation at 55°C
+ carbonate/bicarbonate buffer (0.5 mL, 20% [8.4 g  NaHCO3/13.8 g K2CO3]) 
 pH 9-10
centrifugation at 4500 g for 5 minutes
supernatant extracted two times with 4 mL TBME
evaporation of organic phase under nitrogen at 40 °C
+ 100 µL methanol  SFC-ESI-MS-QQQ analysis
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4 Results and Discussion 
4.1 Synthesis of 2α- and 2β-Hydroxy-17α-methyltestosterone 
 
The synthesis of 2αOHMT, 2βOHMT, and 4OHMT consists of two steps, shown in 
Figure 17. To obtain 2αOHMT (5), 2βOHMT (4), and 4OHMT (6), commercially 
available MT (1) was used as educt. In the first step, MT was treated with sodium 
hydroxide and hydrogen peroxide to obtain a mixture (7:3 peak area ratio from GC-MS) 
of 4β,5β-epoxy-17α-methyltestosterone (2) and 4α,5α-epoxy-17α-methyltestosterone 
(3) (chromatogram Figure 18). GC-EI-MS identified the two isomers with no 
derivatization by comparison with reference mass spectra of 4ξ,5ξ-epoxyandrostane-
3,17-dione, and calculated mass shifts of relevant fragments (Figure 19 and Figure 20).  
Because the intention was to synthesize all three hydroxy metabolites of MT in one 
synthesis, no further purification of the epoxides was performed before the second step. 
Afterwards, the epoxide mixture was dissolved in acetone, and a 25% aqueous solution 
of sulfuric acid was added dropwise. The solution was stirred at room temperature for 
72 hours. Extension of the reaction time and variation of the amount of sulfuric acid 
showed no difference in the synthesis outcome.  
 
Figure 17: Two-step synthesis of the three hydroxylated metabolites 2α-hydroxy-17α-methyltestosterone 
(5) 2β-hydroxy-17α-methyltestosterone (4) and 4-hydroxy-17α-methyltestosterone (6) starting from 17α 
methyltestosterone (1) 
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Figure 18: GC-EI-MS total ion current (TIC) chromatogram of underivatized 4β,5β-epoxy-17α-
methyltestosterone (2) and 4α,5α-epoxy-17α-methyltestosterone (3) 
Literature describes that the acid-catalyzed ring opening of 4β,5β-epoxyandrostane-
3,17-dione will mainly yield 2α-hydroxyandrostane-3,17-dione, where the α,α-epoxide 
will open to 4-hydroxyandrostane-3,17-dione [64]. Similarities for the ring opening of 
(2) and (3) were expected (Figure 21). 
 
Figure 19: GC-EI-MS spectra of 4β,5β-epoxy-17α-methyltestosterone at 70 eV [M]•+= 318.2 
 
Figure 20: GC-EI-MS spectra of 4α,5α-epoxy-17α-methyltestosterone at 70 eV [M]•+= 318.2 
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Figure 21: The predicted chemical reaction of the ring-opening in acid conditions exemplified by 4β,5β-
epoxy-17α-methyltestosterone (2) to 2α-hydroxy-17α-methyltestosterone (5) and 2β-hydroxy-17α-
methyltestosterone (4) 
Step two of the synthesis yielded 4OHMT, 2ξOHMT, and small amounts of byproducts, 
which were not identified. As no separation of the per-TMS derivatives with GC-EI-MS 
was achieved, the reaction mixture was analyzed with LC-ESI-MS [method b)]. 4OHMT 
was identified using commercial reference standard. It eluted later than the coeluting 
2ξOHMT isomers. Separation of the 2-hydroxy isomers could not be achieved with 
method b). The byproduct with m/z 319 may be another hydroxy-17α-
methyltestosterone, m/z 317 might be an oxidized hydroxy-17α-methyltestosterone. The 
expected byproduct 6βOHMT coelute with the 2-hydroxy isomers, as a later investigation 
with commercial reference standard of 6βOHMT showed (Figure 22).  
The predicted opening mechanism to obtain (2ξOHMT) – adapted from Tomoeda et al. 
[60] – is shown in Figure 21. A nucleophilic attack at C2 triggers the ring-opening via the 
2,3-enol. The elimination of the resulting hydroxy group at C5 yielded the two 2-hydroxy 
isomers of MT [(4) and (5)]. The α-form is described as the thermodynamically more 
stable isomer, and the β-form can undergo an inversion [65]. The methyl group at C19 
cause sterical complications in the β-form because both large substitutes are orientated 
in the same direction. Burnett et al. showed that 2β substituents switch the A-ring into 
the inverted chair form [64] (Figure 23; 2αOHMT chair form, 2βOHMT inverted chair 
form). 
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Figure 22: LC-ESI-MS total ion chromatogram of the product mixture showing 2OHMT, 4OHMT, 6OHMT, 
and unidentified byproducts 
The products (0.392 mg) were separated in a semipreparative approach using method a) 
to obtain pure fractions for 4OHMT (18 mg, 0,06 mmol) and 2ξOHMT (56 mg, 
0.17 mmol). GC-EI-MS spectra of the mono- and per-TMS derivatives of both fractions 
for structure verification were received using method g). Separation of the per-TMS 
derivatives of 2ξOHMT was achieved with method h) (Figure 63, annex).  
Derivatization with MSTFA and injection out of ethyl acetate resulted in the mono-TMS 
derivatives of 2αOHMT and 2βOHMT; no bis-TMS derivative was visible in the 
chromatogram. MSTFA only at 70 °C was found to be not strong enough to derivatize the 
sterically hindered hydroxy group at C17, as also reported in literature [66]. The MS 
spectrum of 2αOHMT as mono-TMS shows the base peak at m/z 375.2, which shows a 
direct loss of one CH3 group compared with the molecular ion's theoretical mass 








Figure 23: Structures of 2αOHMT (left) and 2βOHMT (right), showing the tension in the A-ring of 
2βOHMT 
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Figure 24: GC-EI-QTOF-MS chromatogram (TIC) of per-TMS derivatives of 2α-hydroxy-17α-
methyltestosterone and 2β-hydroxy-17α-methyltestosterone, method h) 
The spectrum of the mono-TMS derivative of 2βOHMT shows a similar fragmentation 
pattern as 2αOHMT ([C22H35O3Si]+, [M-CH3-H2O]+, Figure 67 in annex). Only minor 
differences in the fragments were observed. Differentiation of the two hydroxy isomers 
as mono-TMS spectra was not possible by EI-MS. Figure 69 shows the spectra of 
2αOHMT as a per-TMS derivative with the molecular ion [M]•+ = m/z 534. The loss of 
[CH3]• results in the fragment m/z 519. Further fragmentation yield m/z 444 after the 
cleavage of one TMSOH group ([M-TMSOH]•+) and 429 after the loss of TMSOH and 
[CH3]• ([M-CH3-TMSOH]+). The fragment with the m/z 147 is indicative for vicinal TMS 
groups ([TMS-O-DMS]+) [67, 68]. D-ring fragmentation gives m/z 143, also specific for 
17-methyl steroids [68].  
Similar to the mono-TMS derivatives, 2βOHMT (Figure 70) as per-TMS derivative shows 
a similar fragmentation as 2αOHMT. Chromatographic separation was needed to 
discriminate between the two 2-hydroxy isomers (Figure 24). 
  
Figure 25: GC-EI-QTOF-MS spectra of 2α-hydroxy-17α-methyltestosterone as per-TMS derivative 
[M]•+=534.3383 
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Figure 26: GC-EI-QTOF-MS spectra of 2β-hydroxy-17α-methyltestosterone as per-TMS derivative 
[M]•+=534.3379 
GC-EI-QTOF-MS was used to identify the elementary composition and origin of the 
fragments discussed before. All fragments (elementary composition, exact mass, 
accurate mass, and mass error) of both enantiomers are displayed in Table 13 and Table 
14. Additionally, it was used for structure confirmation, together with LC-HRMS 
(LC-ESI-QTOF-MS) and NMR spectroscopy. 
Figure 25 represents the mass spectra obtained after analysis of 2αOHMT as per-TMS 
on the GC-QTOF-MS in scan mode (method g). The [M]•+ ion m/z 534.3383 is the most 
abundant peak in the spectrum ([C29H54O3Si3]•+, mass error 1.50 ppm). The loss of [CH3]• 
results in m/z 519.3144 ([M-CH3]+, mass error 0.58 ppm). As reported for 2OHAED, it 
may be assigned to the loss of the methyl group at C19, C18, or a loss of a methyl group 
of TMS [67]; for 2OHMT, also a loss of C20 is possible. Further fragmentation yields 
[M-CH3-TMSOH]+ with m/z 429.2640 (mass error 0.00 ppm). The loss of one OTMS 
group and [H]• results in the fragment [M-TMSOH]+ m/z 444.2874 with a mass error of 
0.00 ppm. After D-ring fragmentation (loss of [C7H17OSi]•), the fragment m/z 389.2329 
is obtained. It can be explained as the fragment [M-C4H8-TMSOH]+, having a mass error 
of 0.51 ppm [68]. The loss of two TMSOH groups and one methyl group yields [M-195]+ 
and is shown as m/z 339.2140 ([M-CH3-2x TMSOH]+, mass error 0.29 ppm). For 
2OHAED, Kollmeier et al. describe the fragment m/z 267 as an A-ring fragment 
containing two TMS groups [67]. The fragment with m/z 267.1728 in the spectrum of 
2αOHMT ([C13H23O2Si2]+) has a mass error of 0.37 ppm. A fragment often seen in 
hydroxylated steroids with vicinal TMS groups in the A-ring is m/z 147.0656. Because of 
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the proximity of the two TMS groups, the fragment (CH3)2=O+-Si(CH3)3 can be formed 
and is well described in literature [67-69]. This fragment is visible with m/z 147.0656 
(mass error -1.36 ppm). The D-ring fragment with the theoretical mass of 143.0878 
(mass error -6.29 ppm), which indicates the structure of 17-hydroxy-17-methyl-steroids, 
is also present in the spectra beside the non-specific fragment of the TMS group with m/z 
73.0468 (mass error 0.00 ppm) [68]. Another fragment described for oxymesterone by 
Parr et al. is m/z 296.1622, which is correlated with fragmentation in the B-ring (loss of 
[C14H26OSi]•) [68]. In the spectrum of 2αOHMT, a fragment with m/z 297.1669 is visible 
and may be the postulated fragment with an additional proton ([M-C14H25OSi]+) having 
a mass error of -10.77 ppm. 
The spectrum of 2βOHMT (Figure 26) shows similar fragments to the ones described 
above for its enantiomer 2αOHMT. Most likely due to low abundance, m/z 389 and 
m/z 297 are not detected). Only the fragment m/z 269.1378 ([C13H25O2Si2]+, mass 
error -3.72 ppm) shows a two proton shift, compared to 2αOHMT. This fragment is also 
described for oxymesterone by Kollmeier et al. [67].  
HRMS using ESI provided accurate masses of the non-derivatized isomers. The 
elementary composition of 2αOHMT (C20H30O3), [M+H]+ accurate mass 319.2265 (mass 
error -0.94 ppm), and 2βOHMT (C20H30O3), [M+H]+ accurate mass 319.2267 (mass 
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Table 13: Postulated fragments, their exact mass, accurate mass, and the resulting mass errors for tris-
TMS derivatives of 2α-hydroxy-17α-methyltestosterone (GC-QTOF-MS) 







[M]•+ 534.3375 534.3383 1.50 
[M-CH3]+ 519.3141 519.3144 0.58 
[M-TMSOH] •+ 444.2874 444.2874 0.00 
[M-CH3-TMSOH]+ 429.2640 429.2640 0.00 
[M-C3H5-CH3-TMSOH]+ 389.2327 389.2329 0.51 
[M-CH3-2xTMSOH] + 339.2139 339.2140 .029 
[M-C3H5-CH3-TMSOH]+ 297.1701 297.1669 -10.77 
[C13H23O2Si2] •+  267.1231 267.1230 0.37 
[TMS-O-DMS]+ 147.0656 147.0658 1.36 
[C7H15OSi]+ 143.0887 143.0878 -6.29 
[TMS]+ 73.0468 73.0468 -0.00 
Table 14: Postulated fragments, their exact mass, accurate mass, and the resulting mass differences for 
tris-TMS derivatives of 2β-hydroxy-17α-methyltestosterone (GC-QTOF-MS) 







[M]•+ 534.3375 534.3379 0.75 
[M-CH3]+ 519.3141 519.3141 0.00 
[M-TMSOH] •+ 444.2874 444.2874 0.00 
[M-CH3-TMSOH]+ 429.2640 429.2634 -1.40 
[M-CH3-2xTMSOH]+ 339.2139 339.2140 0.29 
[C13H25O2Si2] •+ 269.1388 269.1378 -3.72 
[TMS-O-DMS]+ 147.0656 147.0657 0.68 
[C7H15OSi]+ 143.0887 143.0880 -4.89 
[TMS]+ 73.0468 73.0467 -1.37 
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Figure 27: 1H-NMR spectrum of 2ξ-hydroxy-17α-methyltestosterone enantiomers in CDCl3, insert shows 
zoom at 4.00 - 4.50 ppm 
NMR data was obtained from a solution of 5 mg purified 2ξOHMT in deuterated 
chloroform at 298 K. The spectra were recorded at 500 Hz (1H) and 125 Hz (13C), 
respectively. 2D-NMR experiments (1H,1H-COSY, 1H,13C-HSQC, 1H,13C-HMBC) were 
implemented for structure elucidation. Figure 27 shows the 1H spectrum of a mixture of 
the two isomers (2ξOHMT, chemical shifts of the protons in the molecule are displayed 
in parts per million [ppm]). The zoomed region (4.00 ppm to 4.50 ppm) shows the 
proton's chemical shifts at C2. The 2α-proton (4.19 ppm, dd) is correlated to 2βOHMT. 
At 4.27 ppm (dd), the chemical shift of the 2β-proton of 2αOHMT is located. Double 
bond protons are typically shifted to the downfield region. The proton at C4 was assigned 
to the chemical shift at 5.8 ppm. Figure 28 presents the 13C-NMR DEPTQ spectrum of 
2ξOHMT (chemical shifts of the carbon atoms in the molecule are also displayed in ppm). 
The peak at 199.64 was assigned to C3. Carbonyl functions are typically shifted 
downfield. The peaks at 173.07 (C5) and 120.17 (C4) were assigned to the double bond 
(4-en). Similar to the shifts of the 2α/β protons in the 1H-NMR spectrum, C2 shows two 
different chemical shifts for 2βOHMT (68.55 ppm) and 2αOHMT (69.42 ppm). The 
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positive peaks at 13.89 ppm (C18), 18.03 ppm (C19), and 25.88 ppm (C20) represent the 
three methyl groups of the molecule. For structure confirmation of 2βOHMT and 
2αOHMT 2D-NMR experiments were used. 1H,13C-HSQC was used to assign the protons 
to the corresponding carbons in the molecule. The 2α-proton at 4.27 ppm couples to the 
carbon at 69.42 ppm, while the 2β-proton at 4.19 ppm couples to the carbon at 
68.55 ppm. 1H,1H-COSY (Figure 76, annex), and 1H,13C-HMBC (Figure 77, annex) spectra 
were used to validate the structure. The NMR results were also compared with the 
predicted values of ChemDraw Professional V19.1 and literature data for 
2ξ-hydroxytestosterone [70, 71]. The corresponding values are shown in Table 15. The 
assignment of C atoms in the A-ring, C17 (CH3), C18, and C19, was confirmed with the 
literature data. The predicted values from ChemDraw were comparable to the measured 
and literature values. Only the prediction for C2 was significantly higher than the value 
found in the sample. The predicted and literature values also confirmed the proton 
assignment for 2ξOHMT. 
 
Figure 28: 13C-NMR DEPTQ spectrum of 2ξ-hydroxy-17α-methyltestosterone enantiomers in CDCl3 
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Figure 29: 1H,13C-HSQC spectrum of 2ξ-hydroxy-17α-methyltestosterone in CDCl3, zoomed area of 0.75 - 
2.5 ppm and 5 - 60 ppm 
The 1H-NMR spectrum (Figure 27) was also used to calculate the ratio of the two isomers. 
The isomer mix used to obtain the NMR spectra contained 15% 2βOHMT and 85% 
2αOHMT. The isomer ratio was determined by comparing the C2 proton integrals of both 
isomers in the 1H-NMR spectra (Figure 27). 
To increase the amount of the 2β-isomer Mitsonobu rearrangement was performed [72, 
73] but did not give the desired outcome. Another synthesis approach by obtaining 
2βOHMT via bromination of C6 with N-bromosuccinimide followed by an acetoxylation 
to obtain the 2ξ-acetoxy derivatives, which then were hydrolyzed to the hydroxy 
metabolites as reported by Rao et al. [65], did not yield the desired products.  
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Table 15: Chemical shifts of 2ξ-hydroxy-17α-methyltestosterone (1H-NMR and 13C-NMR) in comparison 
to predicted values and chemical shifts of 2ξ-hydroxytestosterone  from literature [70, 71]; *value for 
4-hydroxytestosterone [71] 
 
Position Own synthesis 
[CDCl3]  







δC [ppm] δH [ppm] δC [ppm] δH [ppm] δC [ppm] δH [ppm] 




n.a. 1.59 / 1.54 
2.38 / 2.49 








69.2 2α: 4.27 
 
2β: 4.19 
3 199.73 ------------- 197.0 ------------- 199.6 -------------- 
4 120.17 5.75 120.8 5.85 120.4 5.81 / 5.80 
5 173.07 ------------- 175.2 ------------- 172.3 -------------- 




n.a. 2.34 /2.26 
2.41 / 2.53 




n.a. 1.02 / 1.01 
1.86 / 1.98 
8 35.94 1.59 36.0 1.14 n.a. 1.57 / 1.71 
9 54.41 0.92 50.3 1.17 n.a. 0.95 / 1.40 
10 40.61 ------------- 41.4 ------------- n.a. -------------- 




n.a. 1.44 / 1.53 
1.60 / 1.80 







1.87 / 1.89 
13 45.26 ------------- 32.8 ------------- n.a. -------------- 
14 50.06 1.16 49.7 1.04 n.a. 0.97 / 1.00 






1.31 / 1.31 
1.62 / 1.59 






1.49 / 1.49 
2.08 / 2.08 
17 81.32 ------------- 82.8 -OH 4.49 220.2 
81.5* 
3.65 / 3.67 
18 13.89 0.89 16.2 0.89 13.8 0.80/ 0.80 
19 18.03 1.28 19.3 1.24 17.9 1.31 / 1.19 
20 25.88 1.18 25.8 1.20 x x 
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Figure 30: GC-EI-QTOF-MS spectra of 4-hydroxy-17α-methyltestosterone as per-TMS derivative 
[M]•+= 534.3382 
4.2 Synthesis of 4-Hydroxy-17α-methyltestosterone 
4OHMT was synthesized from commercially available MT as described in 3.2.4.1. The 
steps of synthesis are described in the section for 2ξOHMT (4.1). An amount of 18 mg 
pure 4OHMT was obtained after the semipreparative purification of the product mixture 
with method a). Spectra of 4OHMT as mono- (Figure 68, annex) and per-TMS 
(Figure 71) derivatives showed a similar fragmentation pattern to the 2ξOHMT isomers. 
The spectrum of the 4OHMT per-TMS-derivative as TOF scan experiment (GC-EI-
QTOF, method g) is shown in Figure 26. The fragments are similar to the fragments 
already discussed in the section above for 2ξOHMT. Table 16 shows all fragments of 
4OHMT, which are discussed in this section. The base peak of m/z 534.3382 is correlated 
to the [M]•+ ion (mass error 1.31 ppm). The loss of [CH3]• results in m/z 519.3134 (mass 
error -1.35 ppm) [67]. A subsequent loss of [TMSOH] gives [M-CH3-TMSOH]+ with 
m/z 429.2630 (mass error -2.33 ppm). The fragment m/z 444.2867 may be explained by 
the loss of one TMSOH group resulting in the fragment [M-TMSOH]•+ with a mass error 
of -1.58 ppm. The loss of [C7H17OSi]• from the D-ring structure yields the fragment 
m/z 389.2325. It can be explained as the fragment [M-C4H8-TMSOH]+, having a mass 
error of -0.51 ppm [68]. After the loss of two TMSOH groups and one methyl group, the 
fragment [M-CH3-2xTMSOH]+ m/z 339.2082 (mass error -16.80 ppm) is detected. The 
A-ring fragment with m/z 267.1226 ([C13H23O2Si2]•+) has a mass error of -1.87 ppm. The 
fragment m/z 147.0656 is present in the spectrum and represents vicinal TMS groups in 
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the A-ring (mass error 0.00 ppm). A well-described fragment of oxymesterone is 
m/z 296.1622, which is correlated with fragmentation in the B-ring (loss of [C14H26OSi]•) 
[68]. This fragment ([M-C14H26OSi]+, m/z 296.1611, mass error -3.71 ppm) has a very low 
abundance but can be observed in the spectra. The characteristic D-ring fragment of 
17-methyl steroids with the accurate mass of 143.0872 (mass error -10.48 ppm) is also 
present in the spectrum besides the non-specific fragment of the TMS group with 
m/z 73.0466 (mass error -2.74 ppm) [68]. The elementary composition of 4OHMT 
(C20H30O3) was verified by LC-HRMS (accurate mass [M+H]+ 319.2268, mass error 
0.00 ppm). 
NMR experiments were obtained from a solution of 5 mg purified 4OHMT in deuterated 
DMSO at 298 K. The spectra were recorded at 500 Hz (1H) and 125 Hz (13C), respectively. 
2D-NMR experiments (1H,1H-COSY, 1H,13C-HSQC, 1H,13C-HMBC) were implemented for 
structure elucidation. As explained in the discussion for 2ξOHMT, integrating the 
1H-NMR spectra and proton assignment was only achieved with 2D-NMR experiments. 
Table 16: Postulated fragments, their exact mass, accurate mass, and the resulting mass differences for 
4-hydroxy-17α-methyltestosterone, GC-QTOF-MS of per-TMS derivative 







[M]•+ 534.3375 534.3382 1.31 
[M-CH3]+ 519.3141 519.3134 -1.35 
[M-TMSOH]•+ 444.2874 444.2867 -1.58 
[M-CH3-TMSOH]+ 429.2640 429.2630 -2.33 
[M-C3H5-CH3-TMSOH]+ 389.2327 389.2325 -0.51 
[M-CH3-2xTMSOH]+ 339.2139 339.2082 -18.28 
[M-C3H5-CH3-TMSOH]+ 296.1622 296.1611 -3.71 
[C13H23O2Si2]•+ 267.1231 267.1226 -1.87 
[TMS-O-DMS]+ 147.0656 147.0656 0.00 
[C7H15OSi]+ 143.0887 143.0872 -10.48 
[TMS] + 73.0468 73.0466 -2.74 
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Figure 31: 1H-NMR spectrum of 4-hydroxy-17α-methyltestosterone in DMSO-d6 
The 1H-NMR spectrum of 4OHMT is displayed in Figure 31 and shows the protons' 
chemical shifts in the molecule. The proton of the hydroxy group at C4 is shifted 
downfield to 7.72 ppm. The proton of the second hydroxy group at C17 is located at 
4.07 ppm. The three methyl groups (C18, C19, C20) were assigned to 0.79 ppm, 
1.13 ppm, and 1.07 ppm. Figure 32 shows the 13C-NMR spectrum of oxymesterone. 
Similar to 2ξOHMT, C3 is shifted downfield to 199.39 ppm. Carbons related to the double 
bond are also shifted downfield to 141.94 ppm (C4) and 139.85 ppm (C5). C17 is shifted 
to 80.08 ppm because of the proximity to the hydroxy group. The correlation between 
protons and carbons in the molecule is displayed in Figure 33 (1H,13C-HSQC). The four 
quaternary carbons (C3, C4, C5, and C17) show no proton binding, as expected. C18, C19, 
and C20 show highly intense signals (14.47 ppm – 0.79 ppm / 17.47 ppm – 1.13 ppm / 
26.57 ppm- 1.07 ppm). To strengthen the structure confirmation, 1H,1H-COSY 
(Figure 78, annex), and 1H,13C-HMBC (Figure 79, annex) were used together with the 
prediction of ChemDraw V19.1 and formestane data from the literature [71] as shown in 
Table 17. Minor deviations between measured and literature values were expected due to 
different solvents (DMSO-d6 [sample] vs. CDCl3 [literature]). Nevertheless, the 
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assignment of all C atoms was confirmed with the literature data. Only the value for C17 
was different (220 ppm [literature] – 80 ppm [measured]) but was expected because of 
the 17-oxo group of 4-hydroxyandrost-4-ene-3,17-dione (formestane). The value for 
4-hydroxytestosterone from the same reference showed a comparable value of 83 ppm 
to the found 80 ppm (both structures have a 17-hydroxy group). The predicted values 
from ChemDraw were comparable to the measured and literature values but differed for 




Figure 32: 13C-NMR spectrum of 4-hydroxy-17α-methyltestosterone in DMSO-d6 
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Figure 33: 1H,13C-HSQC spectrum of 4-hydroxy-17α-methyltestosterone in DMSO-d6 
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Table 17: Chemical shifts of 4-hydroxy-17α-methyltestosterone (1H-NMR and 13C-NMR) in comparison to 
predicted values and chemical shifts of 4-hydroxyandrost-4-ene-3,17-dione from literature [70, 71], 




ChemDraw prediction Literature values for 
 13C / 1H 
4-hydroxyandrost-4-ene-
3,17-dione [71]  
[CDCl3] 
δC [ppm] δH [ppm] δC [ppm] δH [ppm] δC [ppm] δH [ppm] 












3 199.39 ------------- 193.0 ------------- 193.2 -------------- 
4 141.94 -OH 7.72 142.9 -OH 10.68 141.4 -OH 6.16 
5 139.85 ------------- 142.2 ------------- 139.3 -------------- 












8 36.07 1.49 36.0 1.14 34.6 1.65 
9 54.41 0.83 54.0 1.17 54.1 1.01 
10 37.87 ------------- 33.0 ------------- 37.7 -------------- 














13 45.39 ------------- 45.4 ------------- 47.3 -------------- 
14 50.22 1.13 49.7 1.04 50.8 1.30 
















17 80.08 -OH 4.07 82.8 -OH 4.49 220.4 
81.5* 
n.a. 
18 14.47 0.79 16.2 0.89 13.8 0.92 
19 17.26 1.13 19.3 1.24 17.1 1.20 
20 26.57 1.07 25.8 1.20 x x 
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4.3 Synthesis of 19-Hydroxy-17α-methyltestosterone 
19OHMT was synthesized from commercially available 19OHAED via a Grignard 
reaction at position 17. Prior protection of position 3 was performed by stirring a 
methanolic solution of 19OHAED in the presence of acetyl chloride. The stages of 
chemical synthesis are shown in Figure 34. In the first step, acetyl chloride was used to 
eliminate the resulting water from the ketalization of position three. As acetyl chloride is 
very reactive, the hydroxy group at position 19 might be acetylated to give the first 
intermediate product (8). As the raw product of the first step was directly used for step 
two of the synthesis, this structure (8) is only postulated but not verified. The postulated 
ester in position 19 was cleaved during the Grignard reaction, as displayed in Figure 35. 
Further investigation of this prediction was not performed, as the protection of the C19 
hydroxy group would not influence the structure of the product. In the second step, (8) 
was treated with methyl magnesium bromide to introduce the methyl group in position 
17.  
 
Figure 34: Steps of the chemical synthesis of 19-hydroxy-17α-methyltestosterone (10) using 
19-hydroxyandrost-4-en-3,17-dione (7) as educt; first intermediate product (8) after the protection of 
position 3 and second intermediate product (9) after Grignard reaction and hydrolysis with water 















Figure 35: Anticipated reaction mechanism of C19 ester with CH3MgBr to give the unprotected hydroxy 
group 
Liao et al. described that this step mainly gives the 17α-methyl product (19-hydroxy-3,3-
dimethoxy-17α-methyltestosterone, 9) as generally obtained in 17-methylation of 
steroids [61]. 
The isomer 19-hydroxy-3,3-dimethoxy-17β-methyltestosterone may be one byproduct 
but was not detected with the used GC-MS method. Cleavage of the protection group at 
position 3 with hydrochloric acid in methanol gave the desired product 19OHMT (10).  
Figure 36 depicts the GC-EI-MS chromatogram after derivatization of the product 
mixture (GC-EI-MS, method f). 19OHAED has a retention time of 16.3 min and m/z of 
518 (spectrum is displayed in annex Figure 80). The educt spectrum shows the 
characteristic fragment loss of 103 daltons, which correspond with the loss of 
[CH2-OTMS]• (C19) [74]. Most of the educt did not react in the synthesis. Protection of 
both oxo groups (3 and 17) instead of only protecting position 3 might explain this. 
19OHMT, as the desired product, has a retention time (RT) of 17.3 min and m/z 534. 
 
Figure 36: GC-MS chromatogram after TMIS derivatization showing 6 main products unidentified 
byproduct 1 (m/z 444, RT 11.6), unidentified byproduct 2 (m/z 460, RT 13.1 min), unidentified byproduct 
3 (m/z 460, RT 13.8 min), unidentified byproduct 4 (m/z 446, RT 15.0) min, 19OHAED (m/z 518, RT 
16.3 min, educt) and 19OHMT (m/z 534, RT 17.3, product) 
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Figure 37: GC-EI-MS spectra of 19OHMT as per TMS derivative at 70 eV [M]•+= 534.3 
The spectrum of 19OHMT, displayed in Figure 37, shows specific fragments for the 
19-hydroxy group ([M-103]+) and the introduced methyl group in position 17 (m/z 143, 
D-ring fragment of 17-methyl-steroids).  
Other fragments already described for 2ξOHMT and 4OHMT in sections 4.1 and 4.2 are 
also found in the spectrum of 19OHMT. For example, the loss of one TMSOH group 
resulting in [M-90]•+ with m/z 444, or the loss of [CH3]• resulting in m/z 519 ([M-15]+). 
Also, the fragment [C13H23O2Si2]•+ with m/z 267 and m/z 339 showing the fragment 
[M-CH3-2xTMSOH]+ (similarities to 2ξOHMT) were used to identify the structure of 
19OHMT.  
Two main byproducts were produced with [M]•+ of m/z 444 and m/z 460. Both peaks 
(RT 11.6 min and 13.1 min, Figure 80 and Figure 81) show a loss of m/z 103 that 
correlates to an intact 19-hydroxy group. The first byproduct (substance 1, RT 11.6 min, 
Figure 81) did not show the fragment with m/z 143, which indicates a missing 17-methyl-
17-hydroxy structure.  The [M]•+ of m/z 444 and the missing fragment of m/z 143 indicate 
a possible Wagner-Mehrwein (WM) rearrangement in the D-ring. Therefore, substance 1 
(RT 11.6 min) was proposed to be the WM product of 19OHMT, produced during the acid 
catalyzed cleavage of the protection group in position 3. The second byproduct (RT 
13.1 min, substance 2, Figure 82) shows the specific D-ring fragment for 17-methyl-17-
hydroxy steroids of m/z 143. With m/z 460 at RT 13.8 min, the third byproduct 
(substance 3, Figure 83) shows a similar spectrum and may be an isomer of substance 2. 
Fragmentation pattern and molecule peak in the spectra of substance 2 and substance 3 
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may result from an oxidated isomer of 19OHMT as bis-TMS derivative. The molecular 
peak of byproduct 4 (substance 4, Figure 84) at RT 15.0 min shows an m/z of 446, which 
may be explained by the bis-TMS derivative of the educt. 
Nevertheless, the spectrum of substance 4 (Figure 84) also shows both characteristic 
fragments for 19-hydroxy and 17-methyl groups ([M-103]+ and m/z 143), which 
counterfeits the 17-oxo function of 19OHAED. Therefore, no identification of substance 4 
was possible. For an exact confirmation of the byproduct structures, further purification 
and separation of the product mixture and NMR analysis of the pure fractions are 
advisable. As the intention was to synthesize 19OHMT as analytical reference for 
CYP19A1 in vitro study of MT (RT and MRM), no further investigation of the byproducts 
was performed.  
After purifying the product mixture by washing it with ethyl acetate, only a small amount 
of ~3 mg of 19OHMT was obtained. The amount was too small for additional structure 
investigation methods, such as NMR experiments.  
The product, after cleaning, showed a bad solubility in methanol. After filtration, the 
methanolic solution was used to investigate the RT and multiple reaction monitoring and 
source optimization for method d).  
 
Figure 38: SFC-QQQ-MS chromatogram of the steroid mix (4OHMT, MT, 2βOHMT, 2αOHMT, 19OHMT 
[including two unidentified byproducts]) using method d) 
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Figure 38 shows the chromatogram of a mixture of 2ξOHMT, 4OHMT, MT, 19OHMT, 
and its two synthesis byproducts. The product gave three peaks with the same MRM 
(showed as 19OHMT, 19OHMT byproduct 1, and 19OHMT byproduct 2). Later 
investigation of the in vitro study showed the peak at 8.1 min to be the desired 19OHMT.  
The product with RT 17.3 min was postulated to be the desired 19OHMT, taking into 
account the reaction mechanism, the fragmentation pattern of the per-TMS derivative, 
and the chromatographic behavior in SFC (AED-19OHAED/MT-19OHMT). 
19OHMT could be synthesized in small amounts using an adapted method of Liao et al. 
[61]. However, optimization of this method has to be performed to increase this synthesis 
outcome to obtain enough substance for further characterization of the products.  
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4.4 Analytical Method Development 
One central part of the project was developing a chromatographic method, which can 
separate OHMT isomers of interest. Therefore, the well-established systems 
GC-MS(/MS) (section 4.4.1) and LC-MS(/MS) (section 4.4.2) were compared to the 
orthogonal technique of SFC-MS/MS (section 4.4.3). 
4.4.1 GC-MS methods 
Three different GC-MS methods were used in this project. Two of these methods used a 
single quadrupole MS as a detector (method f and g in section 3.2.3.2). HRMS on a GC-
QTOF-MS was performed at the anti-doping laboratory in Rome, using a standardized 
method (method h in section 3.2.3.2). All three methods used identical Agilent 
HP1-Ultra columns (17 m, 200 µm, 0.11 µm) due to its proven success for steroid-TMS 
separation. Method f) was already established for the detection of several underivatized 
and trimethylsilylated steroids. It used a long two gradient from 183 °C to 232 °C with a 
ramp of 3 °C/min (first step) and to 310 °C with a ramp of 40 °C/min (full parameters in 
chapter 3.2.3.2). These parameters ended in a runtime of 21 min. Figure 40 shows that 
the method could not separate the per-TMS derivatives of the hydroxy isomers.  
Derivatization with MSTFA yielded the mono-TMS derivatives of these substances and 
the separation of 2αOHMT, 2βOHMT, and 4OHMT (Figure 39). Nevertheless, no 
separation of 2αOHMT and 6βOHMT was achieved.   
 
 
Figure 39: Overlay of EICs (m/z 375.2) from the mono-TMS derivatives of 2αOHTM, 2βOHMT, 4OHMT, 
and 6βOHMT obtained for method f)  
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Figure 40: Overlay of EICs (m/z 534.3) from the per-TMS derivatives of 2αOHTM, 2βOHMT, 4OHMT, and 
6βOHMT obtained for method f) 
The method was used for monitoring the synthesis of 2ξOHMT and 4OHMT together 
with the LC method b). TMIS contamination in the liner of the GC injector partially led 
to per-TMS derivatization when the mono-TMS samples were injected directly from 
MSTFA. Therefore, MSTFA was evaporated under nitrogen flow, and the resulting 
residue was dissolved in ethyl acetate to avoid the unwanted per-TMS derivatives. 
A steeper first ramp of 50 °C/min (150 °C to 240 °C), and a flatter second ramp of 
3 °C/min (to 266 °C) were used in method g) (full parameters in chapter 3.2.3.2). These 
parameters ended in a much faster runtime but showed no other advantages over 
method f) for the separation of per-TMS derivatives. Method g) was also unable to fully 
separate the per-TMS derivatives of the MT reference standards (Figure 41). With similar 
parameters, Joseph separated 6α/βOHAED from 4OHAED and 2α/αOHAED [4].  
 
Figure 41: Overlay of EICs (m/z 375.2) from the mono-TMS derivatives of 2αOHTM, 2βOHMT, 4OHMT, 
and 6βOHMT obtained for method g)  
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Figure 42: Overlay of EICs (m/z 534.4) from the per-TMS derivatives of 2αOHTM, 2βOHMT, 4OHMT, and 
6βOHMT obtained for method g)  
The chromatogram of the mono-TMS derivatives showed a similar separation as 
method f) (mono-TMS derivatives, Figure 42). The RTs for the different substances for 
method f) and method g) are shown in Table 18. The separation in both GC-EI-MS 
methods was not good enough to separate the isomers.  
As the differentiation of the 2ξOHMT and 4OHMT was also not possible with the 
fragmentation obtained from the MS spectra, optimization of the GC-EI-MS methods 
was not followed up. EI ionization was used for the structure verification via the 
fragmentation pattern of the cleaned synthesis products. 
Method h) was used to measure accurate masses of the synthesis products (2ξOHMT and 
4OHMT). It used a long gradient (ramp 1 °C/min) starting at 200 °C. All four hydroxy 
metabolites as per-TMS derivative were separated from each other (Figure 43). 
Nevertheless, the method struggled in the baseline separation of 4OHMT and 2αOHMT 
(calculated resulting peak resolution 0.63), and the total run time was about 48 minutes. 
GC-MS methods struggle to separate 4-hydroxy metabolites from 2-hydroxy metabolites 
(as per-TMS, [47]). This result was also confirmed in my research project. Martinez-Brito 
et al. only recently developed a GC-MS method for separating 2-, 4- and 6-OHMT, using 
a long temperature gradient (>20 min) and multiple reaction monitoring (MRM) [47]. 
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Figure 43: Overlay of EICs (m/z 534.4) from the per-TMS derivatives of 2αOHTM, 2βOHMT, 4OHMT, 
and 6βOHMT obtained for method h) 
The disadvantages of GC-MS methods are the long run time and the time-consuming 
step of derivatization as described in 1.3. Furthermore, the artefactual building of 
6-hydroxy metabolites in the derivatization process and the missing discrimination 
between 6α- and 6β-hydroxy isomers after derivatization to per-TMS derivatives are 
discussed and might influence the results in GC-MS analysis [47, 75]. 
Method h) was the only GC-MS method capable of separating the per-TMS derivatives 
of the four isomers. Due to the long runtime of the methods, poor separation, the 
additional sample preparation step (advantages and disadvantages explained in section 
1.3), and the missing discrimination between 6α- and 6β-hydroxylated steroids, GC-MS 
methods were discarded for measuring the in vitro and in vivo studies. 
Table 18: RTs of mono- and per-TMS derivatives of 2αOHMT, 2βOHMT, 4OHMT, and 6βOHMT for 
method f) and method g) 
Substance Retention Time [min] 
Method f Method g 
mono-TMS per-TMS mono-TMS per-TMS 
2αOHMT 16.420 17.885 6.098 7.698 
2βOHMT 15.250 17.885 5.664 6.934 
4OHMT 14.979 17.885 5.533 7.651 
6βOHMT 16.388 17.885 6.074 7.595 
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4.4.2 LC-MS methods 
Three LC-MS methods were developed using two different starting points. The first 
method used an achiral reversed phase C18 column (Agilent ZORBAX Eclipse Plus RP 
C18 [1.8 µm, 2.1 x 100 mm], method b) shown in 3.2.1.2). The second and third method 
used a chiral phased column (Agilent Poroshell 120 Chrial-V [2.7 µm, 2.1 x 100 mm], 
method c) shown in 3.2.1.3).  
Method b) used a single quadrupole MS as detector. As all hydroxy isomers have the 
same mass, differentiation of the isomers requires chromatographic separation. The 
method used a gradient from 5% to 95% ACN (solvent b) containing 0.1% formic acid in 
ten minutes (solvent a: water + 0.1% FoOH). It separated the 2ξOHMT isomers from 
4OHMT but struggled in the separation of 2ξOHMT and 6OHMT (Figure 44). The RTs 
of the four isomers for this method are displayed in Table 19. As this method could not 
separate all hydroxy isomers, it was only used for synthesis control. 
To achieve a better separation of all isomers, a LC-MS method was developed using a 
chiral phase column (Agilent Poroshell Chiral-V) and an ESI-QQQ-MS detector. The 
optimized method could separate the 2ξOHMT isomers and 4OHMT but failed in the 
base line separation of 6βOHMT and 2βOHMT (calculated resulting peak resolution 
0.83). An example of the separation is shown in Figure 45.  
 
Figure 44: Overlay of EICs ([M+H]+ 319.1) of the reference substances using method b); showing the 
coeluting 6βOHMT (RT 7.775 min) and 2ξOHMT (RT 8.715 min),  and 4OHMT (RT 10.193 min) 
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Figure 45: LC-ESI-QQQ-MS TIC chromatogram of the reference substances; 6βOHMT (RT 6.008 min), 
2ξOHMT (RT 6.677 min [2αOHMT] and 6.333 min [2βOHMT]) and 4OHMT (RT 7.879 min)  
The method used water (+0.1% FoOH) as solvent a, ACN (+0.1% FoOH) as solvent b, and 
the same gradient as method c) (3.2.1.3). Table 19 shows the RT for all substances of 
interest obtained with this method. Even though MS/MS in MRM mode was utilized, the 
method could not detect the low concentrations of the hydroxy metabolites found in the 
enzyme incubations, as the ionization of the molecules was too low. Figure 85 (annex) 
shows chromatograms of the sample HLM_1 in LC-ESI-QQQ-MS analysis compared to 
the results of the final SFC-ESI-QQQ method. The peak area was used to compare the 
sensitivity of the methods. The finally developed method (shown in 3.2.2.1 and discussed 
in 4.4.3) was more than ten times more sensitive than the LC method. Therefore, no 
further optimization of this LC-ESI-QQQ-MS method was performed. 
 
Table 19: Retention times of the reference standards 2αOHMT, 2βOHMT, 4OHMT, and 6βOHMT for the 
three LC-MS methods (LC-ESI-MS/LC-ESI-QQQ-MS/LC-ESI-QTOF-MS) 





2αOHMT 6.324 6.667 8.715 
2βOHMT 6.324 6.333  8.160 
4OHMT 7.618 7.879 10.193 
6βOHMT 6.324 6.008 7.775 
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Figure 46: Overlay of EICs ([M+H]+ 319.2268) of the reference substances using method c); 6βOHMT (RT 
7.775 min), 2ξOHMT(RT 8.715 min and 8.160 min)  and 4OHMT (RT 10.193 min) 
To increase the ionization for method c) (shown in 3.2.1.3) compared to the previously 
described LC-ESI-QQQ-MS method, 1 mM NH4F was added to both solvents as an 
additive. To dissolve NH4F in solvent b, 2.5% water was included in the solvent mixture. 
The method used the same gradient as the LC-ESI-QQQ-MS method and is depicted in 
section 3.2.1.3. Nevertheless, this method also struggled to separate 2βOHMT and 
6βOHMT (Figure 46).  
Instead of an ESI-QQQ-MS, the LC system was coupled to an ESI-QTOF-MS and 
therefore was used to obtain the accurate masses of underivatized reference material 
(2ξOHMT and 4OHMT). For this purpose, pure fractions of the synthesis products were 
used.  
Most LC-MS methods have problems separating 6-hydroxy metabolites from 2-hydroxy 
metabolites. Nevertheless, only recently, Escobar-Wilches et al. managed to develop a 
UHPLC-MS method to separate, identify, and quantify seven hydroxylated T 
metabolites, including 6β- and 2β-hydroxytestosterone [52].  
Nonetheless, as the GC-MS methods, also the LC-MS methods of this project struggled 
in the complete separation of the isomers and therefore were discarded for the 
measurements of the in vivo and in vitro studies.  
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4.4.3 SFC-MS methods 
SFC, as an orthogonal technique to HPLC and GC-MS, together with MRM, was used to 
separate all metabolites of interest. Several chiral stationary phases were tested. 
Figure 47 compares three chiral stationary phases using a sample that contained both 
2OHMT metabolites, as this was the critical resolution pair in SFC. Using a teicoplanin-
based column (Agilent Poroshell Chiral-T; 2.7 µm, 4.6 x 100 mm), the two 2-hydroxy 
isomers of MT were not separated. However, the ChiralPak IB-U column (Chiral 
Technologies Europe; 1.6 µm, 3.0 x 100 mm) separated the isomers but showed a bad 
peak shape for both isomers. Agilent's Poroshell Chiral-V (vancomycin-based; 2.7 µm, 
4.6 x 100 mm) gave a satisfactory resolution between 2αOHMT and 2βOHMT. Gradient 
optimization was performed to increase the critical resolution (calculated resulting peak 
resolution for 2αOHMT/2βOHMT in the final method was 1.24) and optimize the run 
time.  
 
Figure 47: Comparison of the three chiral phased columns (Agilent Poroshell Chiral-V, Agilent Poroshell 
Chiral-T, and Chiral Chrialpak IB-U); ESI TIC MRM chromatograms of a sample containing 2αOHMT 
and 2βOHMT in a ~5:1 ratio 
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The makeup solvent composition was changed from pure methanol containing 0.1% 
formic acid to a mixture of methanol and water (97.5/2.5; v/v; 1 mM NH4F, 0.1% FoOH) 
following the composition described by Parr et al. [76]. The new makeup solvent 
increased the sensitivity by a factor of ~two compared to the first makeup solvent 
mixture.  
The ion source parameters were optimized with Agilent's source optimizer software 
V10.0 to maximize the sensitivity. For this purpose, the capillary and nozzle voltage, the 
sheeth and drying gas temperature and flow, and the nebulizer pressure were modified 
and compared with the settings of the first method (displayed as 100% in Figure 50). The 
results of this optimization are displayed in Figure 50. Section 3.2.2.1 shows the final 
SFC-ESI-QQQ-MS method parameters used to analyze the in vitro and in vivo studies.  
Additional experiments with an atmospheric pressure chemical ionization (APCI) source 
were performed. The intention was to test if APCI yields a better ionization of the 
steroids. Different makeup solvents containing 10-100 mM NH4F were used for method 
optimization. However, the APCI source showed no advantages, rather disadvantages 
over the ESI source. Figure 49 shows APCI and ESI results for a sample of 2ξOHMT 
(concentration 1 µg/mL). The sensitivity obtained from ESI was roughly 100 times 
higher than with APCI. The results were similar to the results described by Parr et al. for 
other steroids [76]. 
 
Figure 48: Overlay of the normalized MRM chromatograms of reference materials; 4OHMT (RT 
3.842 min) 2ξOHMT (RT 5.188 min [2βOHMT] and 5.565 min [2αOHMT]), and 6βOHMT (RT 6.774 min) 
66  Results and Discussion 
 
 
Figure 49: Comparison of APCI and ESI in positive mode, showing a ~100 (103 vs. 105; red boxes) times 
higher sensitivity for ESI; sample contained 1 ppm 2ξOHMT in a 1:5 ratio 
 
Figure 50: Plotted results of the source optimization for method e). The peak area related to the starting 
point before the optimization [%] is plotted against the tested values for the capillary voltage, nebulizer 
pressure, drying gas flow (DGF), drying gas temperature (DGT), sheath gas flow (SGF), sheath gas 
temperature (SGT), and nozzle voltage 
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4.5 In vitro Hydroxylation of MT 
In vitro studies with pooled human liver microsomes (HLM) or different isolated CYP 
enzymes (CYP19A1, CYP2C19, CYP1A2, and CYP1B1) were performed to investigate the 
formation of the hydroxy metabolites of MT. Therefore, enzyme incubations were 
performed as described in 3.2.6. Test incubations with different substrate concentrations 
(100 µg/mL, 50 µg/mL, and 10 µg/mL) were performed to exclude potential enzyme 
saturation. In most cases, the formation of hydroxylated metabolites was very low. The 
final substrate concentration used for in vitro studies was 100 µg/mL; possible enzyme 
saturation was only detectable for HLM and CYP19A1 (HLM_1 [substrate concentration 
10 µg/mL] and CYP19A1_1 [substrate concentration 10 µg/mL]).  
The enzyme incubation results are presented in the following sections 4.5.1-4.5.3 and 
compared to literature data of structurally related AAS. Those studies aimed to 
investigate the impact of hydroxy metabolites in the metabolization of MT [method d)]. 
The primary metabolites of MT in humans, 5βTHMT, and 5αTHMT, are poorly 
detectable in electrospray ionization [45, 77] and will not be considered in these studies. 
AED incubations were performed as positive control to show similarities and differences. 
Formestane (4-hydroxyandrost-4-ene-3,17-dione) was not available as standard when 
the studies were performed. Therefore, 2α-hydroxyandrost-4-ene-3,17-dione, 
2β-hydroxyandrost-4-ene-3,17-dione, 6β-hydroxyandrost-4-ene-3,17-dione, and 
19-hydroxyandrost-4-ene-3,17-dione were monitored besides AED as substrate in the 
control experiments [method e)]. 
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4.5.1 Biotransformation of MT with HLM  
HLM are commonly used for studies of AAS metabolism [19, 21, 22, 30]. The cytochrome 
P450 isoform 3A4 (CYP3A4) is the most abundant enzyme in human liver metabolism 
[20, 32]. Wang et al. separated and characterized six different CYP450 isozymes from 
HLM in 1983 [78]. The HLM used for this study specifies ten different CYP450 isoforms. 
Because of the wide variety of enzymes, HLM studies can give a good overview of possible 
metabolites that may be expected in humans. The MRM chromatograms of MT, 
2αOHMT, 2βOHMT 4OHMT, 6βOHMT, and 19OHMT after 24-hour incubation of MT 
are displayed in Figure 87 (sample HLM_1; sample HLM_2 Figure 88; annex). 
Biotransformation with HLM resulted in the formation of all five hydroxy metabolites in 
both samples. In comparison, the negative control sample (Figure 98) showed low 
amount of three autoxidation products (2αOHMT, 2βOHMT, and 6βOHMT) besides the 
substrate. The relative peak area (peak area of the substance in correlation to the 
complete peak area of all detected substances [MT, 2αOHMT, 2βOHMT 4OHMT, 
6βOHMT, and 19OHMT]) after correction with the internal standard (MD) was used to 
compare the results. Table 20 represents the comparison of the two HLM incubations to 
the negative control. It shows the corrected areas (absolute and relative [%]) of the 
substrate and its five hydroxy metabolites. The relative results are also illustrated in 
Figure 51. All five hydroxy metabolites of MT were formed in a higher amount compared 
to the negative control.  
 
Figure 51: Plotted results of 2αOHMT, 2βOHMT, 4OHMT, 6βOHMT, and 19OHMT of the two HLM 
incubation studies compared to the negative control sample 
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Figure 52: Comparison of the relative area of hydroxylated metabolites after HLM incubation of MT and 
AED, showing predominant hydroxylation in position 2β and 6β in both substrates 
In the sample HLM_1, the substrate concentration was lowered to 10 µg/mL. Thus, the 
absolute areas were lower than in HLM_2 (100 µg/mL substrate), but relative areas were 
closer to previous literature results. 6βOHMT (RT 6.75 min) represents the main 
metabolite. After 24 hours of incubation, 6βOHMT showed a relative area of 87% (57% 
in HLM_2). The formation of 2βOHMT after 24 hours was 8.28% (relative area, HLM_2 
20.29%). 2αOHMT and 19OHMT was found in both incubations but only in minor 
amounts (2αOHMT 0.77% [HLM_1]/1.61% [HLM_2], 19OHMT 
0.69% [HLM_1]/1.40% [HLM_2]) and 4OHMT was only detected with 0.03% (relative 
area) in both incubations. Incubation with AED showed similar results (Figure 52). 
Therefore, the impact of HLM on the formation of 4OHMT might be negligible. 
The formation rate of 6βOHMT matches the rates of 6β-hydroxytestosterone formation 
after testosterone incubation reported in literature [19, 21, 22]. CYP3A4 is associated as 
the central enzyme in the oxidation process in position six [19, 23, 26, 52]. Rendic et al. 
suggested that the 3-oxo-4-ene-electron effects contribute to the 6β-hydroxy formation 
[26]. Nevertheless, oxidation in 2β position is also described in literature as one major 
pathway in HLM studies [21, 22]. The results of Waxmann et al. [21] (~10% formation of 
2β-hydroxy-testosterone) are similar to the results of HLM_1 (8.28% 2βOHMT). 
HLM_2 showed a lower 6βOHMT/2βOHMT ratio than HLM_1 (~2.5 compared to ~10). 
The HLM in vitro studies with MT and AED showed similar results and matched 
previous work results with different AAS [19-22].  
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6βOHMT and 2βOHMT were identified as major metabolites of MT's hydroxylation 
reaction in HLM incubations. Escobar-Wilches et al. reported similar results for the 
excretion of hydroxylated T metabolites in human urine [52].  
Table 20: Comparison of the absolute and relative (%) peak area of MT, 2αOHMT, 2βOHMT, 4OHMT, 
6βOHMT and 19OHMT after HLM incubation (HLM_1, and HLM_2) and the negative control sample; * 
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4.5.2 Biotransformation of MT with CYP2C19 
The intention of the in vitro studies with CYP2C19 was to evaluate if MT behaves 
similarly to testosterone in the formation of 6β- and 2β hydroxy metabolites [19]. 
The biotransformation of MT with CYP2C19 resulted in the formation of three different 
hydroxylated metabolites. As expected, the MRM chromatograms after 24 hours of 
incubation showed the formation of 2αOHMT, 2βOHMT, and 6βOHMT (Figure 90, 
Figure 91, and Figure 92; annex). 6βOHMT was predicted to be the major hydroxy 
metabolite after CYP2C19 incubation, based on the literature results [19]. Interestingly 
2βOHMT instead of the expected 6βOHMT was formed as the major metabolite. About 
5% of MT was hydroxylated in position 2β, where only ~1% in position 6β. 2αOHMT was 
formed in only minor amounts (~0.1%). Table 21 and Figure 53 illustrate the results of 
the three incubations, which all showed similar outcomes. The results differ from the 
control samples, where AED was incubated with CYP2C19. In these samples, only 
2βOHAED and 6βOHAED were detected besides the substrate, and the concentrations 
of these metabolites were similar to the amount formed in the negative control sample 
of AED. Therefore, no enzymatic hydroxylation reaction with CYP2C19 was observed for 
AED. Figure 54 depicts the results of MT and AED incubation for comparison. The 
2β-hydroxy and 6β-hydroxy metabolite formation was significantly higher for MT than 
AED (p=0.05).  
 
Figure 53: Plotted results of 2αOHMT, 2βOHMT, 4OHMT, 6βOHMT, and 19OHMT of the three CYP2C19 
incubation studies of MT compared to the negative control sample 
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Figure 54: Comparison of the relative area of hydroxylated metabolites of MT and AED, showing MT 
hydroxylation in position 2β and 6β 
The results might indicate that C17 hast to be sp3 hybridized to be hydroxylated in 
position 2β. Yamazaki et al. published that CYP2C19 plays an essential role in the 
oxidation of steroids. AED formation after T incubation and hydroxylation reactions of 
T and progesterone in position 2β and 6β after incubation with CYP2C19 were described 
[19]. 
Incubations of T with human liver microsomes showed comparable results to CYP2C19 
incubations [19]. The results of these studies differ from incubations of MT reported by 
Yamazaki et al., where the formation of 6β-hydroxytestosterone is ten times higher than 
2β-hydroxytestosterone [19]. Further comparison with CYP3A4 as the predominant 
enzyme for hydroxylation reactions in steroid metabolism may give a more in-depth 
insight into the role of CYP2C19 in the metabolization process of MT. Based on the 
presented results, CYP2C19 may be the predominant enzyme to form 2βOHMT. 
MT AED MT AED MT AED MT AED MT AED













Results and Discussion  73 
 
Table 21: Comparison of the relative and absolute (%) peak area of MT, 2αOHMT, 2βOHMT, 4OHMT, 
6βOHMT, and 19OHMT after HLM incubation (CYP2C19_1, CYP2C19_2, and CYP2C19_3) to the 
negative control sample 
 
4.5.3 Biotransformation of MT with CYP1A2 and CYP1B1 
Because the results of the in vitro study of CYP1A2 and CYP1B1 incubations were nearly 
similar, they are displayed and discussed together. These two enzyme studies aimed to 
investigate if MT shows the same or comparable metabolization pattern as reported for 
estrogens [30]. The hypothesis was that CYP1A2 incubations lead to the formation of 
2βOHMT and 4OHMT with preference for 2βOHMT and CYP1B1 incubations vice versa. 
Biotransformation with CYP1A2 resulted in three hydroxylated metabolites of MT. The 
results of all three incubations (MRM chromatograms Figure 93 [CYP1A2_1], Figure 94 
[CYP1A2_2], and Figure 95 [CYP1A2_3]) showed similar results. Over 99% of MT was 
not metabolized to hydroxylated compounds. 6βOHMT was found as the main 
metabolite with an average of 0.7% (relative area). The two 2-hydroxy isomers were 
found in small amounts (2αOHMT 0.02%, 2βOHMT ~0.1%), comparable to the amount 
found in the negative control sample. The amount of 6βOHMT was increased by a factor 
of ~ three during incubation with CYP1A2 compared to incubations without enzyme. 
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Figure 55: Plotted results of 2αOHMT, 2βOHMT, 4OHMT, 6βOHMT, and 19OHMT of the three CYP1A2 
incubation studies compared to the negative control sample 
with CYP1A2. The absolute and relative areas of MT and its metabolites are shown in 
Table 22 and plotted in Figure 55. To exclude enzyme saturation, incubations with lower 
substrate concentrations (50 µg/mL and 10 µg/mL) were performed but could barely be 
analyzed because the concentrations of the metabolites were too low to be detected. The 
results show that CYP1A2 influences the metabolization of MT to 6βOHMT but shows no 
remarkable influence on forming the 2-hydroxy isomers. As only a small amount of the 
parent compound was metabolized in these enzyme incubations, the impact of CYP1A2 
on the metabolism of MT to hydroxylated metabolites can be seen as negligible. 
Incubations with CYP1B1 showed similar results to the incubation of MT with CYP1A2. 
As illustrated in Figure 56 and shown in Table 23, the metabolization rate of MT was 
meager (over 99% MT was not metabolized to hydroxylated metabolites). Only 6βOHMT 
with an average of 0.7% for the two incubations was built in a higher amount than in the 
negative sample. The formation of both 2-hydroxy isomers (2αOHMT 0.02%, 2βOHMT 
~0.1%) was comparable to the amount formed in the negative control sample.  
 
Figure 56: Plotted results of 2αOHMT, 2βOHMT, 4OHMT, 6βOHMT, and 19OHMT of the two CYP1B1 
incubation studies compared to the negative control sample 
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Figure 96 shows the MRM chromatograms of the sample CYP1B1_1 and the absence of 
4OHMT and 19OHMT (sample CYP1B1_2 Figure 97; annex). As for CYP1A2, the impact 
of CYP1B1 on the metabolism of MT can be seen as negligible. 
As discussed before, literature already describes 6β-hydroxy metabolites as autoxidation 
products [47]. The in vitro studies of MT suggest that the formation of small amounts of 
2α- and 2β-hydroxy metabolites also show a correlation to autoxidation. Therefore, 
incubations with AED (positive control) were used to verify this prediction.  
CYP1A2 and CYP1B1 incubations of AED showed comparable results to the MT 
incubations. 6βOHAED and 2βOHAED were formed in the enzyme incubations and also 
the negative control sample. Therefore, these results might indicate minor amounts of 
2βOHMT (~1.5 ng/mL) as an autoxidation product of MT. 
Cheng et al. and Lee et al. published that both enzymes play an essential role in A-ring 
oxidation of estrogens [30, 79]. CYP1A2 was reported to build mainly the 2-hydroxy 
metabolites, where CYP1B1 had a higher impact on the catechol building in position 4 
(4-hydroxyestrogens). The hypothesis that MT behaves like estrogens in CYP1A2 and 
CYP1B1 incubations was not verified.  
 
 
76  Results and Discussion 
 
Table 22: Comparison of the relative and absolute (%) peak area of MT, 2αOHMT, 2βOHMT, 4OHMT, 
6βOHMT and 19OHMT after HLM incubation (CYP1A2_1, CYP1A2_2, and CYP1A2_3) to the negative 
control sample 
 
Table 23: Comparison of the relative and absolute (%) peak area of MT, 2αOHMT, 2βOHMT, 4OHMT, 
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4.5.4 Biotransformation of MT with CYP19A1 
The in vitro study with CYP19A1 aimed to investigate the formation of 2βOHMT and 
19OHMT in the aromatization process of MT to 17α-methyltestosterone. Both substances 
may be hypothesized as intermediate products in the formation of 2β,19-dihydroxy-17α-
methyltestosterone. Monitoring of 17α-methyltestosterone as product of the 
aromatization of MT was not included in this project but will be a part of the following 
projects. Like the HLM incubations, the first sample (CYP19A1_1) was incubated with a 
lower substrate concentration of only 10 µg/mL. The MRM chromatograms of the 
sample CYP19A1_1 are shown in Figure 98. The incubation led to the formation of four 
hydroxylated compounds. As hypothesized, 2βOHMT (10%) and 19OHMT (29%) were 
found as main hydroxylated metabolites. Besides these two metabolites, also 6βOHMT 
was found in a relatively high amount (5%). As seen in the other incubation studies, 
2αOHMT was formed, but only in a minor amount (0.4%).  
Instead of 10 µg/mL in CYP19A1_1, for the samples CYP19A1_2 and CYP19A1_3, a 
substrate concentration of 100 µg/mL was used (similar to the negative control sample). 
For these two incubations, 2βOHMT (1.3%) and 19OHMT (8.3%) represented the main 
hydroxylated products but in lower relative amounts than the sample CYP19A1_1. 
Similar to the sample CYP19A1_1, also 6βOHMT (1%) and 2αOHMT (0.05%) were 
found. The corrected absolute areas of the 2-hydroxy isomers were equal in all three 
replicates of incubations.  
 
Figure 57: Plotted results of 2αOHMT, 2βOHMT, 4OHMT, 6βOHMT, and 19OHMT of the three aromatase 
incubation studies compared to the negative control sample 
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Figure 58: Comparison of the relative area of hydroxylated metabolites of MT and AED, showing 
hydroxylation in position 2β and 19 for both substrates 
These results for 2ξOHMT may indicate a saturation of the enzyme. However, the 
absolute areas of 6βOHMT and 19OHMT in the samples with 100 µg/mL substrate 
concentration (CYP19A1_2 [Figure 99] and CYP19A1_3 [Figure 100]) showed an 
increase compared to sample with lower substrate concentration (10 µg/mL, sample 
CYP19A1_1). The overall metabolization rate for the study with 10 µg/mL substrate 
concentration was about 50% (CYP19A1_1) and 10% for the incubations with higher 
substrate concentrations (CYP19A1_2 and CYP19A1_3). The corresponding peak areas 
are illustrated in Figure 57 and displayed in Table 24. 
The A-ring aromatization process is already discussed in the literature but not 
completely clarified [31, 34, 80]. Several mechanisms of the last step in the aromatization 
are discussed. One prediction is hydroxylation at C2 and C19 (2β,19-hydroxy-17α-
methyltestosterone; as discussed in 1.2.1), leading to the loss of water and formic acid 
[31, 34]. The main metabolite of the considered substances in all three incubations with 
aromatase was 19OHMT, with 29% / 8.3% (relative area). As described for other 
endogenous steroids, the hydroxylation in position 19 showed the major pathway in 
aromatization that leads to 17α-methylestradiol. Therefore, the finding of 19OHMT was 
expected as one of the main metabolites because it represents the first step of the 
aromatization. The formation of 2βOHMT was much lower (10%, respectively ~1,3%) 
than 19OHMT. 
MT AED MT AED MT AED MT AED MT AED
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Nevertheless, the formation of 2βOHMT as one of the intermediate products in the 
aromatization of MT was verified with these results. The results of AED incubation with 
CYP19A1 strengthen this statement. Figure 58 shows the results of both incubation 
studies (MT and AED as positive control). The oxidation of C2 in the aromatization 
process for MT and AED preferred the 2β position. For future work, 2β,19-dihydroxy-
17α-methyltestosterone has to be synthesized, and time-depending incubations with 
CYP19A1 will be performed to get a better overview of the last step in the aromatization 
of androgens and confirmation of the postulated mechanism. Also, incubations of 
2βOHMT and 19OHMT as substrate with aromatase will give a better understanding of 
the aromatization process in the metabolism of MT. 
Table 24: Comparison of the relative and absolute (%) peak area of MT, 2αOHMT, 2βOHMT, 4OHMT, 
6βOHMT, and 19OHMT after HLM incubation (CYP19A1_1, CYP19A1_2, and CYP19A1_3) to the negative 
control sample; * sample CYP19A1_1 had a substrate concentration of only 10 µg/mL 
 
4.5.5 Conclusion of the Biotransformation Studies of MT 
The in vitro studies with MT showed different outcomes. The only hydroxylated 
compound found in all incubations was 6βOHMT, which is consistent with literature 
data [19, 22, 23, 26, 32]. 2βOHMT was found as the major metabolite of CYP2C19 
incubations. It was also found in the incubations with HLM, CYP19A1, and in small 
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The finding of 2βOHMT in the CYP19A1 incubations showed its influence in the 
aromatization process of androgens. 2αOHMT was found in every incubation but only in 
small amounts.  4OHMT was only detected in the HLM incubations. Several aspects may 
explain these findings. First, the extraction of 4-hydroxy-3-oxo-4-ene steroids is highly 
influenced by the pH [68]. Therefore, 4OHMT may not be extracted correctly. Second, 
the ionization efficiency of 4OHMT is not as good as 2ξOHMT (about 1:5). Furthermore, 
the formation of 4OHMT in the metabolism of MT might be so low that its influence is 
negligible. 
The results of CYP1A2 and CYP1B1 incubations (only 6βOHMT in minimal amount) 
indicate that the role of these enzymes in the metabolism of MT is negligible. 
As expected, 19OHMT was found after incubations with aromatase, as the hydroxylation 
of C19 is well described in the aromatization process of androgens [34]. 
The negative control sample showed 2βOHMT and 6βOHMT as autoxidation products. 
These results were confirmed by in vivo studies with AED yielding similar results. 
Table 25 illustrates the overview of the biotransformation studies of MT. 
Table 25: Overview of the results of the in vivo studies of MT;  showing the finding of the metabolite in 
the specific incubation; () showing the finding in a small amount, comparable to the negative control 
sample 
 2αOHMT 2βOHMT 4OHMT 6βOHMT 19OHMT 
HLM      
CYP2C19      
CYP1A2 () ()    
CYP1B1 () ()    
CYp19A1      
Negative      
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4.6 In vivo Hydroxylation of MT 
An in vivo study was performed to investigate the human metabolism of MT. Urine 
samples were obtained before and 130 hours after administering 10 mg MT as a tablet 
(Metadren®) to a healthy volunteer (male, 50 years, 80 kg). The recommendations 
described in the Helsinki Declaration were fulfilled for this study [81]. Preparation of the 
samples followed the protocol described in 3.2.7. β-Glucuronidase was used to cleave the 
glucuronidated phase-II-metabolites. Testosterone-d3-glucuronide was added as an 
internal standard to confirm the enzyme activity of the β-glucuronidase in each sample. 
The resulting liberated testosterone-d3 has a RT of 4.5 min (example peak in the MRM 
chromatogram of 2βOHMT in Figure 59) and is dominant in all samples. The enzyme 
activity was monitored only in qualitative way and not in quantitative way.  
The focus was set to the formation of 2βOHMT, 4OHMT, and 6βOHMT, as no signal for 
the transition for 19OHMT at the corresponding RT was detected, and the qualifier 
transitions did not identify 2αOHMT in the urine samples. Figure 59 depicts the MRM 
chromatograms of the blank urine (MT00). MT was identified in a minimal amount, 
which might correlate to carry over problems of the method itself. Nevertheless, as the 
amount was nearly not detectable, it was assumed that there was no influence on the 
other samples. The blank urine showed the absence of hydroxylated metabolites 
(2βOHMT, 4OHMT, 6βOHMT). However, the transition m/z 319183 of 4OHMT 
showed a peak (also in all other samples) with a small RT shift towards a shorter RT (RT 
3.72 min). 6βOHMT (RT 6.75 min) showed similar problems as 4OHMT. The transition 
of m/z 319283 showed an artifact peak in the blank (also in all other samples) with a 
small retention time shift towards a smaller RT (6.58 min).  
The results of the sample 5.5 hours after administration (MT02) are shown in Figure 60. 
This sample was used as an example because it contains the parent compound and all 
three hydroxy metabolites. The most abundant metabolite found in this sample was 
2βOHMT. 4OHMT was also detected in the sample. However, the transition problem of 
4OHMT, described for the blank urine, challanges its identification. The quantifier  
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Figure 59: MRM chromatograms of the blank sample MT00 showing MRM of MT, 2βOHMT, 4OHMT, and 
6βOHMT 
 
Figure 60: MRM chromatograms of the sample MT02 (5.5 hours after administration) showing MRM of 
MT, 2βOHMT, 4OHMT, and 6βOHMT 
 (m/z 319113) and one of the qualifiers (m/z 319125) are detectable. A shoulder 
building at the artifact peak from the qualifier transition m/z 319183 was visible. 
Therefore, the exact integration of this shoulder was not possible. This problem was 
found in all samples where a quantifier peak (m/z 319  183) for 4OHMT was detected. 
Therefore, only the qualifier m/z 319  125 was used to identify 4OHMT in the urine 
samples. Similar to this, a shoulder building was also present for 6βOHMT but, different 
from 4OHMT, in the quantifier transition (m/z 319  283). Therefore, integration of the 
quantifier peak of 6βOHMT was performed manually. Overall, only minor amounts of 
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hydroxylated metabolites were found compared to relatively high amounts of 
unmetabolized MT. The excretion pattern of the three hydroxy metabolites is depicted in 
Figure 61. 2βOHMT as the main metabolite was detected from the 5.5 hours urine to the 
14.5 hours urine after the MT administration. 6βOHMT was only found in the first two 
samples (5.5 and 8 hours after the administration) and at a much lower concentration 
than 2βOHMT. The concentration was visualized as peak area because this in vivo study 
intends to gain information about the qualitative and not the quantitative extend of 
metabolite formation in men. 4OHMT was found in the urine after 5.5 hours and until 
22 hours after administration in very low concentrations. 
As already described in the literature, the two reduced metabolites of MT, 5αTHMT and 
5βTHMT, are the main metabolites found in the human metabolism of MT (see 1.2.3). 
Joseph found 2βOHAED as the main hydroxy metabolite after AED administration. He 
also considered investigating if 2β-hydroxylation might give long term metabolites [4]. 
Incubation of MT with HLM (4.5.1) showed a high percentage of 2βOHMT formed after 
24 hours of incubation (3.2.6). After these results, 2βOHMT was expected to be found in 
the urine.  
 
Figure 61: Urinary excretion of 2βOHMT, 4OHMT, and 6βOHMT in the first 24 hours after 
administration of 10 mg MT to one healthy man (samples MT00 to MT06) 
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4OHMT seemed to have no significant influence on the metabolism of MT in in vitro 
studies. Nevertheless, as the WADA prohibits oxymesterone, it was also investigated in 
the obtained samples. Because CYP3A4 is the main enzyme in human metabolism, 
6βOHMT was expected to be found in the urine. 
Unlike Martinez-Brito et al., 4OHMT was found only in small amounts (peak area) 
compared to 2βOHMT [47]. The concentration might vary because the pH strongly 
influences the extraction rate of 4-hydroxy metabolites [68]. Also, the ionization of 
4OHMT was about five times lower than the ionization of the 2-hydroxy isomers. The 
ionization is exemplified in Figure 62, showing the MRM chromatograms of 4OHMT and 
2ξOHMT (concentration 10 ng/mL both; 2αOHMT ~8.5 ng/mL, 2βOHTM ~1.5 ng/mL). 
Martinez-Brito et al. described a coeluting artifact of 6βOHMT, which might be formed 
in the derivatization reaction [47]. The SFC measurement results of the in vivo samples 
showed similarities to that even without derivatization. These results show that the 
formation of the artifact is not related to the derivatization reaction rather than possibly 
being part of the urine sample itself or the process of liberating the phase-II-metabolites. 
 
 
Figure 62: Overlay of MRM chromatograms of 2αOHMT (concentration ~8.5 ng/mL accordingly to the 
ratio of 2ξOHMT determined by 1H-NMR [section 4.1 - NMR part]), 2βOHMT (concentration ~1.5 ng/mL 
accordingly to the ratio of 2ξOHMT determined by 1H-NMR [section 4.1 - NMR part]) and 4OHMT 
(concentration 10 ng/mL) 
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Compared to the results of Escobar-Wilches et al. [52], the excretion of MT showed 
similarities for 2β and 6β hydroxylation as the main hydroxylated metabolites for T/MT 
in men. However, Escobar-Wilches et al. [52] found 6β-hydroxytestosterone to be the 
main metabolite excreted by men, which intraindividual differences might explain.  
Overall, the in vivo study showed that the hydroxylated metabolites 2βOHMT, 4OHMT, 
and 6βOHMT were detected in urine after MT administration. The hypothesis of 
2βOHMT as a long-term marker for MT abuse could not be confirmed (max 14.5 hours), 
as the well-described reduced metabolites 5αTHMT and 5βTHMT can be detected up to 
103 hours after administration by GC-QQQ-MS  in the same urine samples [47] (urine 
samples for the in vivo study was obtained from Martinez-Brito et al.). 
Further investigations of the matrix effect’s impact on the analysis of human urine 
samples have to be performed to optimize the developed SFC-MS/MS method. 
Therefore, optimization of the ionization of the steroids will be performed. New source 
techniques like UniSpray ionization might be the key to optimize the limit of 
detection/quantification [82]. A second approach will be the optimization of sample 
preparation. 
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5 Summary and Outlook 
Anabolic androgenic steroids (AAS) are commonly used as performance-enhancing 
drugs (PEDs) in sports because of their anabolic effects. Nearly half of the adverse 
analytical findings (AAF) in 2019 are correlated to AAS misuse [83]. The metabolization 
process plays an essential role in the analysis of endogenous and exogenous steroids. 
Therefore, investigations on drug metabolizing and steroidogenic CYP enzymes are 
important in antidoping research. The most common reaction catalyzed by CYP enzymes 
in phase-I-metabolism is the introduction of a hydroxy group.  
Currently, analysis of AAS is mostly performed using GC-MS systems. These methods 
usually correlate with laborious sample preparation and extended run times compared 
to LC-MS(/MS) methods. On the other hand, LC-MS(/MS) methods have a lower 
separation efficiency than GC-MS systems. SFC, as an orthogonal analytical approach, 
was used to separate the hydroxy metabolites of MT.  
This project aimed to get a more in-depth look at the metabolization and analysis of MT, 
an AAS prohibited as PED in sport by the WADA [1], focusing on hydroxylated 
metabolites and the aromatization process. Therefore, reference material of 2αOHMT, 
2βOHMT, and 4OHMT was synthesized and characterized by HRMS and NMR. In vitro 
studies with HLM, CYP2C19, CYP1A2, CYP1B1, and CYP19A1 and an in vivo study with 
one healthy male volunteer were conducted to investigate the formation of hydroxylated 
MT metabolites. Because existing and developed GC-MS(/MS) and LC-MS(/MS) 
methods could not separate the hydroxylated metabolites of interest, an SFC-MS/MS 
method was developed, which gave a good separation. SFC showed its orthogonality by 
means of the elution order 4OHMT>2βOHMT>2αOHMT>6βOHMT, which differed 
from GC (2βOHTM>6βOHMT>4OHTM>2αOHMT, as per-TMS) and LC 
(6βOHMT>2βOHMT>2αOHMT>4OHMT).  
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Finally, the formation of 2βOHMT in HLM and CYP2C19 incubation were verified with 
synthesized reference material, where CYP2C19 may show the predominant way in its 
formation. Additionally, the presence of 2βOHMT after CYP19A1 incubation shows its 
influence in the aromatization of MT. 
Investigation of urine samples after MT administration showed the formation of 
2βOHMT, 6βOHMT, and 4OHMT. However, all three metabolites were only detected to 
a maximum of 22 hours after the administration and in very low concentrations. 
Thus, hydroxylated metabolites of MT cannot be seen as superior metabolites over the 
classical MT metabolites 5αTHMT and 5βTHMT [45]. 
Future work may focus on developing an SFC-HRMS method to investigate the 
formation of unknown hydroxy metabolites. As only recently described by Savill et al., 
incubation studies with different cell lines may be a good alternative for in vivo studies 
with steroids [84]. Further, the synthesis and characterization of possible metabolite 
structures will be the next step in investigating the hydroxylated metabolome. Boldenone 
is the AAS with the majority of reported AAF according to the WADA Testing Figures 
[83]. Therefore, boldenone, or its corresponding 17-methyl analog metandienone, might 
be an interesting substance for this kind of study. 
In addition, further experiments on the aromatization of MT with 2βOHMT and 
19OHMT as substrate, and the identification of 2β,19-dihydroxymethyltestosterone as 
intermediate with synthesized reference material are needed.   
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6 Zusammenfassung und Ausblick 
Anabol androgene Steroide (AAS) werden aufgrund ihrer anabolen Wirkung häufig als 
leistungssteigernde Mittel (PEDs) im Sport eingesetzt. Fast die Hälfte der 
unerwünschten analytischen Befunde (AAF) im Jahr 2019 korreliert mit dem 
Missbrauch von AAS [83]. Eine wesentliche Rolle bei der Detektion von endogenen und 
exogenen Steroiden in Urinproben spielt die Metabolisierung. Daher sind 
Untersuchungen zu arzneimittelmetabolisierenden und steroidogenen CYP-Enzymen in 
der Antidopingforschung wichtig. Die häufigste Reaktion, die von CYP-Enzymen im 
Phase-I-Metabolismus katalysiert wird, ist die Einführung einer Hydroxygruppe.  
Die Analyse von AAS wird derzeit meist mit GC-MS-Systemen durchgeführt. Diese 
Methoden sind in der Regel mit einer aufwendigen Probenvorbereitung und längeren 
Laufzeiten im Vergleich zu LC-MS(/MS)-Methoden verbunden. Auf der anderen Seite 
haben LC-MS(/MS)-Methoden eine geringere Trenneffizienz im Vergleich zu GC-MS-
Systemen. Die SFC als orthogonaler analytischer Ansatz wurde zur Trennung der 
Hydroxymetaboliten von MT verwendet. 
Ziel dieses Projektes war es, die Metabolisierung und Analyse von MT, einem von der 
WADA als PED im Sport verbotenen AAS [1], genauer zu untersuchen, wobei der Fokus 
auf hydroxylierte Metabolite und die Aromatisierung lag. Dazu wurde Referenzmaterial 
von 2αOHMT, 2βOHMT und 4OHMT synthetisiert und mittels HRMS und NMR 
charakterisiert. In vitro Versuche mit HLM, CYP2C19, CYP1A2, CYP1B1 und CYP19A1 
sowie ein in vivo Versuch mit einem gesunden männlichen Probanden wurden 
durchgeführt, um die Entstehung von hydroxylierten MT-Metaboliten zu untersuchen. 
Da bestehende und entwickelte GC-MS(/MS)- und LC-MS(/MS)-Methoden nicht in der 
Lage waren, die hydroxylierten Metaboliten zu trennen, wurde eine SFC-MS/MS-
Methode entwickelt, die eine gute Trennung ergab. Die SFC zeigte seine Orthogonalität 
an Hand der Elutionsfolge 4OHMT>2βOHMT>2αOHMT>6βOHMT, welche sich 
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grundlegend von der GC (2βOHTM>6βOHMT>4OHTM>2αOHMT, als per-TMS) und  
der LC (6βOHMT>2βOHMT>2αOHMT>4OHMT) unterschied. 
Die Entstehung von 2βOHMT in HLM und CYP2C19 Inkubation mit wurde mit 
synthetisiertem Referenzmaterial verifiziert, wobei CYP2C19 offenbar den 
vorherrschenden Weg bei der Entstehung von 2βOHMT zeigt. Das Vorhandensein von 
2βOHMT nach Inkubation mit CYP19A1 zeigt dessen Einfluss auf die Aromatisierung 
von MT. 
Die Untersuchung von Urinproben nach Einnahme von MT zeigte die Entstehung von 
2βOHMT, 6βOHMT und 4OHMT. Alle drei Metaboliten wurden jedoch nur bis maximal 
22 Stunden nach der Verabreichung und in sehr geringen Konzentrationen 
nachgewiesen. 
Somit können hydroxylierte Metabolite von MT gegenüber den klassischen MT 
Metaboliten 5αTHMT und 5βTHMT nicht als übergeordnet angesehen werden [45]. 
Zukünftige Arbeiten könnten sich auf die Entwicklung einer SFC-HRMS-Methode 
beschäftigen, um die Bildung von unbekannten hydroxylierten Metaboliten zu 
untersuchen. Wie erst kürzlich von Savill et al. beschrieben, können Inkubationsstudien 
mit verschiedenen Zelllinien eine gute Alternative für in vivo Studien mit Steroiden sein 
[84]. Die Synthese und Charakterisierung möglicher weiterer Metabolitstrukturen 
werden der nächste Schritt bei der Untersuchung des Phase-I-Metabolismus von MT 
sein. Boldenon ist das AAS mit den meisten berichteten AAF gemäß des WADA Testing 
Figures Report [83]. Daher könnte Boldenon oder sein entsprechendes 17-Methyl 
Analogon Metandienon eine interessante Substanz für diese Art von Studie sein. 
Zudem sind weitere Versuche zu der Aromatisierung von MT mit 2βOHMT und 
19OHMT als Substrat, und die Identifizierung von 2β,19-Dihydroxymethyltestosterone 
als Zwischenprodukt mit synthetisierter Referenzsubstanz nötig.
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Figure 63: GC-EI-MS chromatogram (EIC) of 2αOHMT (RT 6.130 min) and 2βOHMT (RT 5.684 min) as 
mono-TMS derivative 
 
Figure 64:GC-EI-MS chromatogram (EIC) of 4OHMT as mono-TMS derivative (RT 5.565 min) 
 
Figure 65: GC-EI-MS chromatogram (TIC) of 4OHMT as per-TMS derivative (RT 5.565 min) 
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Figure 66: GC-EI-MS spectra of 2αOHMT as mono TMS derivative at 70 eV [M-15]•+= 375.2 
 
 
Figure 67: GC-EI-MS spectra of 2βOHMT as mono TMS derivative at 70 eV [M-15]•+= 375.2 
 
 
Figure 68:GC-EI-MS spectra of 4OHMT as mono TMS derivative at 70 eV [M-15]•+= 375.3 
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Figure 69: GC-EI-MS spectra of 2αOHMT as per TMS derivative at 70 eV [M]•+= 534.4 
 
 
Figure 70: GC-EI-MS spectra of 2βOHMT as per TMS derivative at 70 eV [M]•+= 534.4 
 
 
Figure 71: GC-EI-MS spectra of 4OHMT as per TMS derivative at 70 eV [M]•+= 534.4 
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Figure 75: 13C NMR spectrum of 2ξ-hydroxy-17α-methyltestosterone 
 
Figure 76: 1H,1H-COSY spectrum of 2ξ-hydroxy-17α-methyltestosterone, inserts show zoom areas of 4.1 – 
4.35 ppm and 4.0 – 4.5 ppm / 4.1 - 4.4 ppm and 2.2 – 2.6 ppm 
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Figure 77: 1H,13C-HMBC spectrum of 2ξ-hydroxy-17α-methyltestosterone 
 
Figure 78: 1H,1H-COSY spectrum of 4-hydroxy-17α-methyltestosterone 
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Figure 79: 1H,13C-HMBC spectrum of 4-hydroxy-17α-methyltestosterone 
 
Figure 80:GC-EI-MS spectra of 19OHAED as per-TMS derivative at 70 eV [M]•+= 518.3 
 
Figure 81: GC-EI-MS spectra of byproduct 1 of 19OHMT synthesis after TMIS derivatization at 70 eV 
[M]•+= 444.3 
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Figure 83: GC-EI-MS spectra of byproduct 3 of 19OHMT synthesis after TMIS derivatization at 70 eV 
[M]•+= 460.2 
 
Figure 84: GC-EI-MS spectra of byproduct 4 of 19OHMT synthesis after TMIS derivatization at 70 eV 
[M]•+= 446.3 
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Figure 85: LC (upper chromatogram) vs. SFC (lower chromatogram) method; comparison exemplified 
with sample HLM_1 with 6βOHMT (area 15923065 vs. 990511) and 2βOHMT (area 2443467 vs. 47775) 
 
Figure 86: Chromatograms MRM (MT, 2αOHMT, 2βOHMT,4OHMT, 6βOHMT, 19OHMT) of the negative 
control of in vitro metabolization  
 
Figure 87: Chromatograms MRM of MT, 2αOHMT, 2βOHMT 4OHMT, 6βOHMT and 19OHMT after 24-
hour incubation of MT with pooled human liver microsomes (sample HLM_1) 
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Figure 88: Chromatograms MRM of MT, 2αOHMT, 2βOHMT 4OHMT, 6βOHMT and 19OHMT after 24-
hour incubation of MT with pooled human liver microsomes (sample HLM_2) 
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Figure 90: Chromatograms MRM of MT, 2αOHMT, 2βOHMT  4OHMT, 6βOHMT and 19OHMT after 24-
hour incubation of MT with CYP2C19 (sample (CYP2C19_1) 
 
Figure 91: Chromatograms MRM of MT, 2αOHMT, 2βOHMT 4OHMT, 6βOHMT and 19OHMT after 24-
hour incubation of MT with CYP2C19 (sample CYP2C19_2) 
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Figure 92: Chromatograms MRM of MT, 2αOHMT, 2βOHMT 4OHMT, 6βOHMT and 19OHMT after 24-
hour incubation of MT with CYP2C19 (sample CYP2C19_3) 
 
 
Figure 93: Chromatograms MRM of MT, 2αOHMT, 2βOHMT  4OHMT, 6βOHMT and 19OHMT after 24-
hour incubation of MT with CYP1A2 (sample CYP1A2_1) 
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Figure 94: Chromatograms MRM of MT, 2αOHMT, 2βOHMT 4OHMT, 6βOHMT, and 19OHMT after 24-
hour incubation of MT with CYP1A2 (sample CYP1A2_2) 
 
 
Figure 95: Chromatograms MRM of MT, 2αOHMT, 2βOHMT 4OHMT, 6βOHMT and 19OHMT after 24-
hour incubation of MT with CYP1A2 (sample CYP1A2_3) 
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Figure 96: Chromatograms MRM of MT, 2αOHMT, 2βOHMT  4OHMT, 6βOHMT and 19OHMT after 24-
hour incubation of MT with CYP1B1 (sample CYP1B1_1) 
 
Figure 97: Chromatograms MRM of MT, 2αOHMT, 2βOHMT 4OHMT, 6βOHMT and 19OHMT after 24-
hour incubation of MT with CYP1B1 (sample CYP1B1_2) 
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Figure 98: Chromatograms MRM of MT, 2αOHMT, 2βOHMT  4OHMT, 6βOHMT and 19OHMT after 24-
hour incubation of MT with aromatase (sample CYP19_1) 
 
Figure 99: Chromatograms MRM of MT, 2αOHMT, 2βOHMT 4OHMT, 6βOHMT and 19OHMT after 24-
hour incubation of MT with aromatase (sample CYP19_2) 
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Figure 100: Chromatograms MRM of MT, 2αOHMT, 2βOHMT 4OHMT, 6βOHMT and 19OHMT after 24-
hour incubation of MT with aromatase (sample CYP19_3) 
 
